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A fact is a simple statement that everyone believes.  It is innocent, unless 
found guilty.  An hypothesis is a novel suggestion that no one wants to 
believe.  It is guilty, until found effective.  - Edward Teller 
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Abstract 
Adetunji T Toriola. Epidemiological study of the role of vitamin D in the 
aetiology of ovarian cancer. National Institute for Health and Welfare (THL), 
Research 47. 126 pages. Helsinki, Finland 2010.  
ISBN 978-952-245-380-8 (printed), ISBN 978-952-245-381-5 (pdf) 
 
Ovarian cancer is a very lethal gynaecological cancer because its symptoms 
are insidious and majority of the patients present with advanced stage 
disease. There is considerable geographic variation in the incidence and 
mortality of the disease. The gonadotrophin, hormonal, incessant ovulation 
and inflammation hypotheses have all been proposed to explain its aetiology 
and while epidemiological studies offer some support for aspects of each 
hypothesis, the contribution of other hitherto under-investigated factors 
cannot be discountenanced.  
 
Ecological, experimental and dietary studies suggest that vitamin D may 
offer some protection against ovarian cancer but there is dearth of 
epidemiological studies investigating this association using the best marker 
for vitamin D; serum 25-hydroxyvitamin D (25-OHD). The aim of this thesis 
was to investigate the association between vitamin D and ovarian cancer 
utilizing serum 25-OHD concentrations which is the most reliable way to 
determine an individual’s vitamin D status. 
 
The studies in the thesis are a series of case-control studies nested within 
the Finnish Maternity Cohort (FMC) which is a population-based serum 
biorepository, maintained at -25oC, containing the first trimester serum 
samples of almost all pregnant Finnish women since 1983. Ovarian cancer 
cases and suitably matched controls were identified after linkages with the 
nation-wide Finnish Cancer Registry (FCR) and Statistics, Finland.  
 
The validity of our results depends to a large extent on how measurable and 
preserved the vitamin D metabolite, 25-OHD, is within serum samples that 
have been stored for many years. Therefore, in order to avoid differential 
misclassification in our studies, our first objective was to determine the 
stability of 25-OHD and androstenedione in serum samples that had been 
stored for up to 24 years. We observed the expected marked seasonal 
differences in serum 25-OHD concentrations for all the years studied. The 
mean serum 25-OHD levels were significantly higher in summer (44.0 
nmol/L) compared to winter (33.4 nmol/L, p-value ≤ 0.001). There was no 
evidence to suggest systematic degradation of 25-OHD in stored sera, 
implying that 25-OHD is very stable in serum samples stored at-25oC for 
many years.  
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In the second study involving 201 ovarian cancer cases diagnosed within 10 
years of serum sampling and 398 season, age and parity-matched controls, 
we observed no overall association between serum 25-OHD concentrations 
and ovarian cancer risk (OR 1.8, 95% CI 0.9 – 3.5 comparing lowest to 
highest quintile) but women with insufficient serum 25-OHD concentrations 
(< 75 nmol/L) appeared to be at increased risk of ovarian cancer (OR 2.7, 
95% CI 1.0 – 7.9) compared to those with sufficient concentrations (≥ 75 
nmol/L).  
 
 In study III, we sought to determine whether calcium and vitamin D act 
independently or jointly and whether each modifies the action of the other on 
ovarian cancer risk. Women within the highest quartile of calcium 
concentration had significantly reduced risk of ovarian cancer while women 
within the highest quartile of serum 25-OHD concentration had borderline 
reduced risk of ovarian cancer compared to those within the lowest. Women 
with sufficient serum 25-OHD levels had a significantly reduced risk of 
ovarian cancer compared to women with insufficient serum levels (OR 0.32, 
95% CI 0.12-0.91). While calcium was independently associated with a 
reduced risk of ovarian cancer regardless of serum 25-OHD levels, (OR 0.41, 
95% CI 0.19-087), vitamin D was independently associated with a non-
significantly reduced risk of ovarian cancer (OR 0.51, 95% CI 0.29-1.05). We 
observed no evidence of effect modification between calcium and vitamin D 
with regards to ovarian cancer. 
 
A perceived weakness in epidemiological studies of vitamin D and ovarian 
cancer is the use of one time serum 25-OHD measurement to indicate over 
time vitamin D status. In the only study so far that has measured serum 25-
OHD twice, over a long period of time, among cases and controls; we found 
evidence to suggest that maintaining consistently high serum 25-OHD levels 
over many years during summer may be associated with a reduced risk of 
ovarian cancer. Women whose serum 25-OHD levels were above the 
season specific median values on both sampling occasions had a borderline 
reduced risk of ovarian cancer (OR 0.21 95% CI 0.05-0.99) compared to 
other women with consistently low or fluctuating serum 25-OHD levels. No 
such protective effect was however observed among women who donated 
their samples during winter.  
 
 
Key words: ovarian cancer, vitamin D, 25-hydroxyvitamin D, calcium, 
epidemiology, biobank, cancer registry, prospective study, nested case-
control, longitudinal 
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Johtuen oireiden salakavaluudesta useimmat munasarjasyöpätapaukset todetaan pitkälle 
edenneinä, ja munasarjasyöpä on hyvin tappava gynekologinen syöpä. Maantieteellisesti 
taudin ilmaantuvuus ja kuolleisuus tautiin vaihtelevat huomattavasti. Munasarjasyövän syyksi 
on esitetty gonadotropiinia, muuta hormonaalista syytä, keskeytymättömiä ovulaatiota ja 
tulehdusta. Vaikka jokaisen hypoteesin tueksi on esittää epidemiologista todistusaineistoa 
muiden, toistaiseksi vähän tutkittujen, tekijöiden osuutta ei voi sulkea pois. 
 
Ekologisten, kokeellisten ja ravitsemustutkimusten perusteella D-vitamiini voi suojata mu-
nasarjasyövältä, mutta tutkimukset, jotka hyödyntävät parasta D-vitamiinin mittaustapaa, 
seerumin 25-hydroksi D (25-OHD) vitamiinimääritystä, puuttuvat. Tämän väitöskirjatutkimuk-
sen tarkoituksena oli tutkia D-vitamiinin ja munasarjasyövän yhteyttä käyttäen hyväksi see-
rumin 25-OHD tasoja – luotettavinta tapaa määrittää yksilön D-vitamiinistatus. 
 
Tässä väitöskirjassa esitettävät työt ovat sarja Äitikohorttiin (Finnish Maternity Cohort, FMC) 
upotettuja tapaus-verrokkitutkimuksia. FMC-seerumipankki on väestöpohjainen seerumi-
pankki, jossa lähes kaikkien Suomessa vuodesta 1983 raskaana olleiden naisten ensimmäi-
sen raskaus kolmanneksen seeruminäytettä säilytetään -25° C:ssa. Munasarjasyöpätapauk-
set ja kaltaistetut verrokit identifiointiin yhdistämällä tietoja Syöpärekisterin ja Tilastokeskuk-
sen kanssa.     
 
Tulostemme oikeellisuus riippuu paljolti siitä, miten hyvin D-vitamiinin 25-OHD aineenvaih-
duntatuote on säilynyt ja mitattavissa vuosi säilytetyissä seeruminäytteissä. Sen vuoksi, vält-
tääksemme virheluokitusta, ensimmäinen tavoitteemme oli määrittää 25-OHD:n ja andros-
tenedionin säilyminen seeruminäytteissä, joita oli säilytetty jopa 24 vuotta. Havaitsimme odo-
tetut, vuodenajasta johtuvat seerumin 25-OHD tasojen erot kaikkina seurantavuosina. Kes-
kimääräinen seerumin 25-OHD taso oli merkitsevästi korkeampi kesällä (44.0 nmol/l) talveen 
(33.4 nmol/l) verrattuna (p<0.001). Emme havainneet merkkejä systemaattisesta 25-OHD 
kadosta säilytetyissä seerumeissa, mikä viittaa siihen, että 25-OHD pysyy muuttumattomana 
useiden vuosien ajan -25° C:ssa säilytetyissä seeruminäytteissä.    
 
Toisessa tutkimuksessa, joka koski 201 munasarjasyöpätapausta, jotka oli diagnostisoitu 10 
vuoden kuluessa seeruminäytteen ottamisesta, ja 398 vuodenajan, iän ja raskauksien mää-
rän suhteen kaltaistettua verrokkia emme havainneet yhteyttä seerumin 25-OHD pitoisuuden 
ja munasarjasyöpäriskin välillä (OR 1.8, 95% CI 0.9 – 3.5) vertailtaessa alimman ja ylimmän 
neljänneksen D-vitamiinitason omanneita tutkittavia. Naisilla, joilla oli suositusten mukaan 
riittämätön 25-OHD taso (<75 nmol/l) näytti kuitenkin olevan kohonnut munasarjasyövän riski 
(OR 2.7, 95% CI 1.0 – 7.9) verrattuna riittävät tasot (> 75 nmol/l) omanneisiin naisiin. 
 
Kolmannessa tutkimuksessa selvitimme toimivatko kalsium ja D vitamiini riippumattomasti 
vai muuntelevatko ne toistensa vaikutusta munasarjasyöpäriskiin. Naisilla, jotka olivat kalsi-
um tasojensa suhteen korkeimmassa neljänneksessä, oli merkitsevästi vähentynyt munasar-
jasyöpä-riski kun taas naisten, jotka olivat korkeimmassa D vitamiinineljänneksessä, mu-
nasarjasyöpä-riskin vähenemisen tilastollinen merkitsevyys jäi rajalle. Naisilla, joilla oli riittä-
vät 25-OHD tasot oli merkitsevästä alentunut munasarjasyöpäriski (OR 0.32, 95% CI 0.12 – 
0.91). Kalsiumiin tilastollisesti merkitsevästi liittyvä alentunut munasarjasyöpäriski oli riippu-
maton seerumin 25-OHD tasoista (OR 0.41, 95% CI 0.19 – 0.87). D vitamiiniin liittyvä alen-
tunut munasarjasyöpä-riski (OR 0.51, 95% CI 0.29 –  1.05) oli riippumaton. Emme havain-
neet viitteitä, että kalsium ja D vitamiini muuntelisivat toistensa vaikusta suhteessa munasar-
jasyöpään. 
 
D vitamiinia ja munasarjasyöpää koskeneiden epidemiologisten tutkimusten todettu heikkous 
on ollut yhden seeruminäytteen käyttö arvioitaessa elimistön D vitamiinistatusta yli ajan. 
Toistaiseksi ainoassa tutkimuksessa, jossa seerumin 25-OHD tasoja on mitattu kaksi kertaa 
pitkällä aikavälillä, havaitsimme, että korkean seerumi 25-OHD tason säilyttäminen pitkän 
aikaa voi liittyä alentuneeseen munasarjasyöpäriskiin. Naisilla, joiden seerumin 25-OHD 
tasot olivat vuodenajan keskimääräisiä tasoja korkeammat molemmissa näytteissä oli alen-
tunut riski sairastua munasarjasyöpään (OR 0.21, 95% CI 0.05 – 0.99). Tätä, tilastollisen 
merkitsevyyden rajalla ollutta, suojavaikutusta ei havaittu naisilla, joiden näytteet oli otettu 
talvella.         
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1  INTRODUCTION 
Ovarian cancer is without doubt a very perplexing disease, and defining the 
aetiological risk factors has so far proved challenging. This, together with the 
fact that ovarian cancer symptoms are poorly characterized, prolonging its 
diagnosis, and makes it the most lethal gynaecological cancer.  
 
An important insight into the likely aetiological factors is the marked 
geographical variations in the incidence of the disease and immigration 
studies which reveal that the incidence of the disease among immigrants 
from low-risk to high-risk areas tends to catch up with that of the high-risk 
area within a generation. This implies that environmental factors are very 
important determinants of ovarian cancer aetiology.  
 
Among the factors which may be associated with ovarian cancer risk, the 
roles of sex hormones have been mostly studied because the overt disease 
is often associated with altered hormone states. Recent studies have, 
however, suggested that other pathways especially the vitamin D endocrine 
system may be involved in ovarian cancer risk but the potentials of these 
alternatives have not been thoroughly investigated.  Previous studies that 
had delved into ovarian cancer-vitamin D link were mainly ecological and 
dietary with inherent weaknesses to establish a definite relationship between 
vitamin D and ovarian cancer.  
 
The Finnish Maternity Cohort (FMC) biobank, with its serial serum samples, 
offers a very unique opportunity to investigate the relationship between pre-
diagnostic vitamin D status (as measured by serum vitamin D levels) and 
ovarian cancer, and to determine whether factors which modify serum 
vitamin D concentrations affect this relationship 
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2  LITERATURE REVIEW 
2.1  Pathology and histological classification of ovarian  
       cancers 
 
Ovarian cancer is broadly divided into three major groups: sex cord stromal 
tumours, germ cell tumours and surface epithelial stromal tumours 
depending on the tissue/anatomic structures from which the tumours 
originate (Scully  and Sobin 1999, Chen et al 2003, Jaffe 2003). Each group 
is equally subdivided into various subtypes. Occasionally, two or more 
subtypes may be present in one tumour, in which case, it is called a mixed 
tumour and if a tumour subtype contributes more than 10% of the tumour 
mass, it is specified in the name (Seidman et al 2003, Soslow 2008). The 
surface epithelial stromal tumours are the most common group and they 
account for 80-90% of ovarian cancers in most industrialised countries 
(Chen et al 2003) 
 
2.1.1  Sex cord-stromal tumours 
 
These tumours arise from mesenchymal and mesonephric embryonic origins 
and account for about 7% of all ovarian cancers (Chen et al 2003). Because 
of their cellular origin, they are usually associated with endocrine 
abnormalities, particularly estrogenic but occasionally androgenic (Roth 
2006). The major subtypes are (Roth 2006) 
 
1. Granulosa cell tumours, with two types: a) the adult type which 
represents 95% of all ovarian granulosa cell tumours, usually occur in 
post-menopausal women and are associated with overproduction of 
estrogen, and b) the juvenile type, which may occur before puberty and 
cause precocious sexual development. 
2. Thecomas. These comprise lipid containing cells similar to those of the 
theca interna. 
3. Fibrosarcomas. These are dense, large masses made up of spindle-
shaped cells with a storiform pattern. 
4. Sertoli cell tumours. These tumours arise from rete ovarii and rete testis.  
5. Sertoli-Leydig cell tumours. These tumours are admixture of epithelial 
and testicular cells and usually cause both androgenic (virilisation) and 
estrogenic manifestations. 
6. Steroid cell tumours. These tumours comprise ovarian cancer cells that 
resemble steroid hormone secreting cells. 
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2.1.2  Germ cell tumours 
 
These tumours arise from cells derived from the primordial germ cells and 
are the rarest ovarian cancers in western countries accounting for about 3% 
of cases (Talerman 1994, William et al 1997). They constitute a large 
proportion of the ovarian cancers diagnosed among children and 
adolescents (Chen 2003).  
 
1. Dysgerminomas. These are the most common ovarian germ cell tumours 
with most cases occurring during adolescence and early adulthood.  
2. Yolk sac tumours, also known as endodermal sinus tumours. The 
cellular architecture of yolk sac tumours is very similar to those of the 
primitive yolk sac. They express high levels of alpha-fetoprotein (AFP). 
3. Embryonal carcinoma. These are usually large, solid tumours with 
haemorrhagic and necrotic areas. They also produce AFP and human 
chorionic gonadotrophin (HCG). 
4. Choriocarcinoma. These tumours are formed by trophoblastic cells and 
may be non-gestational, where they are unrelated to pregnancy (majority) 
or gestational when they occur just after a pregnancy. HCG is the tumour 
marker of choriocarcinoma. 
5. Teratoma. They develop from totipotential germ cells and thus contain all 
three germ cell layers; ectoderm, mesoderm and endoderm.  
 
2.1.3  Surface epithelial-stromal carcinomas 
 
These tumours account for about 90% of all ovarian cancers encountered in 
western populations (Scully et al 1998, Prat 2004). There are about five 
major subtypes which differ with respect to epidemiological and genetic risk 
factors, origin, molecular events during oncogenesis and response to 
treatment (Weiss et al 1996, Soslow 2008, Gilks and Prat 2009).  
 
1. Serous carcinoma is by far the most common type of epithelial-stromal 
carcinomas. Previously, it was thought that serous carcinomas 
accounted for about 50% of all epithelial-stromal tumours but based on 
modern histotyping criteria, serous carcinomas are now thought to 
account for between 67.5% and 80% of all epithelial tumours (Seidman 
2004). These cancers display a wide morphological spectrum but most 
consist of papillary, solid areas with slit-like appearances resembling a 
labyrinth. They overexpress p53 and WT1 (Wilms Tumour 1 suppression 
gene) in about 80% of tumours (Soslow 2008, Gilks and Prat 2009).  
 
An important advance in ovarian cancer histopathology was the 
realisation that serous carcinomas comprise two very distinct cancers 
with different underlying pathogenesis, molecular events and behaviour. 
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Serous carcinomas are divided into High-Grade Serous Carcinoma 
(HGSC) and Low-Grade Serous Carcinoma (LGSC) (Shih and Kurman 
2004). HGSCs are predominant, have high mitotic rates, with more than 
3-fold variations in nuclear size as compared to the LGSCs. Likewise, 
only HGSCs are associated with abnormalities in BRCA1 or BRCA2 and 
p53 genes while LGSCs are more likely to have k-ras or b-raf mutations 
(Soslow 2008, Gilks and Prat 2009).  
 
2. Endometroid carcinoma. It is presently estimated that endometroid 
carcinomas account for about 10% of epithelial-stromal carcinomas, from 
the previously estimated 10-25% (Gilks and Prat 2009). This is because 
endometroid carcinoma shares a substantial morphologic overlap with 
serous carcinoma, especially HGSC, and many cases previously 
diagnosed as endometroid carcinomas were later found to be serous 
carcinomas (Gilks and Prat 2009). Endometroid carcinomas are usually 
associated with endometriosis (42% of cases) and endometrial 
carcinomas (20% of cases). The most common genetic abnormalities 
observed in endometroid carcinomas are somatic mutations in beta-
catenin and PTEN genes. Unlike other ovarian cancers, most cases of 
endometroid carcinomas are FIGO stage 1 at diagnosis (Soslow 2008, 
Gilks and Prat 2009). 
 
3. Mucinous carcinomas. They have mucin-rich cytoplasm, usually with 
mucin vacuoles. They comprise about 3% of epithelial-stromal 
carcinomas (Soslow 2008). Previously, ovarian metastases of 
extraovarian mucin-producing adenocarcinomas were erroneously 
classified as being of primary ovarian origin, which accounted for their 
higher prevalence in the past. Primary mucinous ovarian carcinomas are 
usually large, unilateral, confined to the ovarian and without involvement 
of the ovarian surface in contrast to metastases. They preferentially 
express cytokeratin 7 (CK7). (Soslow 2008, Gilks and Prat 2009). 
 
4. Clear cell carcinoma. Clear cell carcinomas are made up of hobnail cells 
with clear cytoplasm. They are rare and a majority of them are 
associated with endometriosis, where they arise in endometriotic cysts 
(Chen et al 2003, Gilks and Prat 2009). 
 
5. Transitional cell carcinomas. These are very rare and are made up of 
low-grade cells with longitudinal nuclear grooves, arranged in broad 
papillae. They bear a striking morphological resemblance to urothelial 
carcinomas (Soslow 2008). 
 
6. Mixed epithelial carcinomas. These occur when the tumour comprises at 
least 2 histologically distinct subtypes, each contributing at least 10% to 
the tumour architecture. The most common variant is a combination of 
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endometroid and clear cell carcinoma since they both frequently arise 
within endometriosis (Soslow 2008).  
 
 
2.1.3.1  Origin of Surface epithelial-stromal carcinomas 
 
A long-held concept is that epithelial-stromal carcinomas arise from the 
ovarian surface epithelium (OSE), being mesothelial in origin (Ressa et al 
1993, Nicosia et al 1999, Auersperg et al 1998), and subsequently undergo 
metaplastic transformation into different cell types (serous, endometroid, 
mucinous and clear cell), which are Mullerian in origin. Thereafter, they 
undergo neoplastic changes within the hormone rich cortical inclusion cysts 
of the ovarian parenchyma (Mittal et al 1993, Deligdisch et al 1995, Scully 
1995, Blaustein et al 1992). Thus, histologically, the ovarian surface 
epithelium is very different from its supposed derivatives, viz a viz serous, 
endometroid, mucinous, clear cell and transitional carcinomas. According to 
this theory, malignant ovarian tumours can only arise after a specific cell-
type (mesothelial) has completely changed its differentiation lineage 
(Mullerian) (Dubeau 2008). Likewise, the ovarian surface epithelium is 
monolayered, expresses little or no E-cadherin while many epithelial ovarian 
cancers express E-cadherin and exhibit complex histological differentiation 
patterns (Naora 2005).  This seeming developmental aberration together 
with the fact that no ovarian carcinoma precursor lesions have been 
identified within the coelomic surface epithelium has opened new vistas in 
the characterization of the origin of epithelial carcinomas.  
 
One of the new theories, backed by genetic and morphologic evidence 
proposes that some ovarian carcinomas are likely to originate from the 
Mullerian system (Dubeau 1999). Serous, endometroid, clear cell and 
mucinous carcinomas morphologically resemble the epithelia of the fallopian 
tube, endometrium and endocervix respectively, all of which are derived 
from the Mullerian ducts. At the molecular level, this theory is backed by the 
observation of Cheng and colleagues that serous, endometroid and 
mucinous carcinomas express the same HOX genes as epithelial cells from 
normal fallopian tube, endometrium and endocervix, respectively (Cheng et 
al 2005).  
 
The HOX genes are involved in morphogenesis of different segments of the 
female reproductive tract and they are highly specific for the different 
segments (Cheng et al 2005, Dubeau 2008). With regard to some serous 
tumours, it is thought that normal epithelial cells from the fimbriated end of 
the fallopian tube may dislodge when the fimbriated end is in contact with 
the ovarian surface and implant on the site of rupture where ovulation 
occurred causing an inclusion cyst to form (Dubeau 2008, Kurman and Shih 
2010). These inclusion cysts may then become malignant supporting the 
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earlier held notion that serous carcinomas may develop from inclusion cysts 
but through a process of implantation of tubal (Mullerian type) tissue rather 
than through metaplasia from ovarian surface epithelium (Dubeau 2008). 
Further evidence supporting a tubal origin for most HGSCs include the 
expression of PAX8, a Mullerian marker, but not calretinin, a mesothelial 
marker (Kurman and Shih 2010), and observations that obliteration of some 
parts of the Mullerian tract in the absence of ovarian ablation can protect 
against ovarian cancer. 
 
While aspects of each of these theories are probably valid, none of them 
completely explains all aspects of ovarian carcinogenesis and the search for 
an all-encompassing theory to explain the origin of ovarian cancer, is far 
from over. This is of particular importance given the fact that the various 
histological subtypes of ovarian cancer have different reproductive (Titus-
Ernstoff et al 2001), and hence hormonal, risk factors and the hormonal and 
similar milieu under which ovarian cancer develops, though have been 
explored in previous studies, need to be expanded further.  
 
2.1.4  Borderline tumours of the ovary 
 
These comprise a separate group of tumours, with similar epidemiological 
but different pathological characteristics to the malignant tumours (Lukanova 
and Kaaks 2006). Histo-pathologically, they are mainly serous, mucinous 
and endometroid tumours but they occur in younger age groups, present at 
earlier stages and have better prognosis compared to the malignant tumours 
(Lukanova and Kaaks 2005). Grossly, borderline tumours are similar to 
benign tumours but they usually have more exuberant projections within the 
cystic cavity in the case of serous tumours and more solid areas in the case 
of mucinous tumours but the solid areas are smaller, with less haemorrhagic 
zones compared with malignant tumours (Chen et al 2003).  
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Figure 1. Age standardized incidence rate (ASR) of ovarian cancer, 
worldwide, 2008 
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Figure 2. Crude rate of ovarian cancer, worldwide 2008 
 
 
2.2  Descriptive Epidemiology of ovarian cancer 
 
Ovarian cancer is the sixth most incident cancer (4% of cases) and the 
seventh most common cause of cancer death (4.2% deaths) among women 
worldwide (Parkin et al 2005). It is the second most common gynaecological 
cancer (19% and 29% of all gynaecological cancers in developing and 
developed countries respectively) but the most lethal (Sankaranarayanan 
and Ferlay 2006).  
 
There are marked geographical differences in the incidence and mortality 
rates of ovarian cancer with an almost four-fold difference in rates observed 
between the highest and the lowest incidence regions (GLOBOCAN 2008, 
IARC). The highest age-standardized incident rates are observed in 
Northern Europe (12.1/100,000), Central and Eastern Europe (11.1/100,000) 
while Western and Southern Africa have the lowest age-standardized 
incidence rates (3.8/100,000) (GLOBOCAN 2008, IARC). Likewise, trends in 
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incidence and mortality rates have varied widely across the world. Incidence 
rates have been declining in Northern America and most parts of Northern 
Europe but they have been steadily increasing in some of the Central and 
Eastern European countries (Bray et al 2005). The increases in parts of 
Europe are however, more conspicuous among older women compared to 
younger women but a different pattern is projected worldwide. According to 
the latest WHO projections, a 30% increase in the annual number of new 
cases, worldwide, is expected by the year 2020, mostly driven by increasing 
incidence among women less than 65 years (GLOBOCAN 2008, IARC).  
 
Figure 3.  
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Figure 4.  
 
 
 
2.3  Etiologic Factors 
 
Established risk factors for ovarian cancer include age, family history of 
ovarian cancer, the use of hormone replacement therapy (HRT) and 
infertility while inflammation is a strongly suspected risk factor. On the other 
hand, increasing parity, use of hormonal contraception, (oral contraceptive 
pills, OCP), tubal ligation and hysterectomy are known to be protective while 
lactation is suspected to be protective (Whittemore et al 1992, Riman et al 
2002, Sueblinvong and Carney 2009, Permuth-Wey and Sellers 2009). 
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2.3.1  Age 
 
Incidence rates of ovarian cancer increase with age. The majority of cases 
(80 to 90%) are diagnosed during the peri and postmenopausal periods, the 
median age at diagnosis being between 58 and 65 years (Holschneider and 
Berek 2000). Hereditary ovarian cancer however develops at an earlier age 
with each successive generation (Goldberg et al 1997). 
 
2.3.2  Family history 
 
About 10% of ovarian cancers are hereditary (Antoniou et al 2000). Germ-
line mutations in the high penetrance BRCA1 and BRCA2 tumour 
suppressor genes contribute 90% of the hereditary component. Whereas the 
lifetime risk of ovarian cancer in the general population is 2%, it approaches 
40-65% and 20% among those with BRCA1 and BRCA2 mutations, 
respectively (Ford et al 1998, King et al 2003). Hereditary ovarian cancer is 
also associated with the Lynch Syndrome (hereditary nonpolyposis 
colorectal cancer) (Lynch et al 2009). This is due to mutations in the 
mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2 genes). 
Carriers of these defective genes are susceptible to cancers arising in 
different parts of the body particularly the colorectum, ovary, endometrium, 
stomach and small intestine (Lynch et al 2009). 
 
2.3.3  Hormone Replacement Therapy 
 
Initially, the impact of hormone replacement therapy (HRT) on ovarian 
cancer risk was controversial. While some studies observed no increased 
risk of ovarian cancer associated with HRT, (Sit et al 2002, Purdie et al 
1999), others did (Lacey et al 2002, Lacey et al 2006). However, the two 
most recent and largest studies to date have observed that not only is HRT 
associated with increased risk of ovarian cancer and ovarian cancer 
mortality, the risk increases with duration of use (Beral et al 2007, Morch et 
al 2009). Furthermore, the risk was evident regardless of HRT formulation, 
regimen, route of administration, reproductive history, previous use of oral 
contraceptives and socio-economic status. The million women study (Beral 
et al 2007) however noted that the risk did vary by tumour histology with the 
greatest risks observed for serous tumours. Risk among past users is similar 
to that of never users indicating that the risk disappears after stopping HRT 
use. According to the million women study, the use of HRT resulted in 1,300 
and 1,000 additional ovarian cancer cases and deaths respectively in the UK 
between 1991 and 2009. 
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2.3.4  Inflammation 
 
An association between inflammation and ovarian cancer has been 
suggested because factors which cause local inflammation of the ovary are 
associated with increased risk of ovarian cancer (Ness and Cottreau 1999). 
These are perineal talc use, endometriosis and pelvic inflammatory disease 
(Risch and Howe 1995, Brinton et al 1997, Langseth et al 2008). Likewise, 
gynaecological operations like tubal ligation, hysterectomy which prevent 
retrograde transport of inflammatory substances from the lower genital tract 
to the ovaries and the use of non-steroidal anti-inflammatory drugs (NSAIDs) 
are associated with reduced risk of the disease (Green et al 1997, 
Schildkraut et al 2007). Of the three prospective studies that have 
investigated the relationship between circulating C-reactive protein (CRP) 
which is an inflammatory biomarker and ovarian cancer risk, two observed 
increased risk of ovarian cancer among women within the highest CRP 
concentrations (McSorley et al 2007, Toriola et al 2010) while the third 
though did not observe an overall association, found that risk of ovarian 
cancer was higher among women with very high CRP concentrations 
(Lundin et al 2009).  
 
2.3.5  Infertility 
 
Many studies have observed a positive relationship between infertility and 
ovarian cancer (Rossing et al 1994, Venn et al 1995). The increased risk 
appears to be most pronounced among nulligravid women who have been 
trying to become pregnant for many years but the excess risk was not 
associated with the use of fertility drugs (Ness et al 2002). Among women 
who have been pregnant, nulliparous women, but not parous women, are at 
increased risk, especially those whose infertility manifested late in 
reproductive life. Role for specific type of infertility has not been confirmed 
(Ness et al 2002, Rossing et al 2004) but it is noteworthy that pelvic 
inflammatory disease has been associated with both tubal factor infertility 
and ovarian cancer. 
 
2.3.6  Parity 
 
One of the most consistent findings in ovarian cancer epidemiology is the 
protective effect conferred by full-term pregnancy. Parity reduces the risk of 
ovarian cancer by 30 to 70% and each additional pregnancy is estimated to 
confer an extra 10 to 20% reduction in the risk (Cramer et al 1983, 
Wittenberg J et al 1999, Adami et al 1994, Whittemore et al 1992). It is 
postulated that pregnancy reduces ovarian cancer risk by causing 
anovulation, suppressing pituitary gonadotrophins secretion and temporarily 
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interrupting the retrograde transport of menstrual blood flow through the 
fallopian tubes, hence allowing time for apoptosis. If parity protects against 
ovarian cancer only through these mechanisms, a similar level of protection 
might be associated with lactation since the same mechanisms operate 
during lactation.  The protective effects of lactation are weaker compared to 
those observed with parity and not all studies have observed a protective 
effect (Whittemore 1992 et al, Rosenblatt et al 1993, Danforth et al 2007). 
Thus, the altered hormonal milieu of pregnancy is also likely to play an 
important role. The effects of incomplete pregnancies, whether spontaneous 
or induced are less clear (Cramer et al 1983, Whittemore et al 1992, Riman 
et al 2002). 
 
2.3.7  Gynecological surgery 
 
Majority of studies have observed a protective effect for tubal ligation and 
hysterectomy against ovarian cancer (Riman et al 2002, Hankinson et al 
1993, Green et al 1997). According to some studies the protection can last 
up to twenty years after the surgery (Miracle-McMahill et al 1997, Green A et 
al 1997). It is also acknowledged that the magnitude of protection offered by 
tubal ligation is higher than that of hysterectomy. Among high risk women, 
the risk reduction may be as high as 90% (Domcheck and Rebbeck 2007). 
These two gynaecological procedures are believed to reduce ovarian cancer 
risk by preventing communication between the ovaries and the external 
genital tract and thus precluding the ascension of carcinogenic substances 
from the external genital tract to the ovaries.  
 
2.3.8  Oral contraceptive pill 
 
OCP use protects against ovarian cancer regardless of other known risk 
factors (Hankinson et al 1992, La Vecchia 2006). A recent collaborative re-
analysis of 45 studies with 23,257 cases and 87,303 controls revealed that 
the protection offered by OCPs can last for as long as 30 years after 
cessation of use, even though the risk reduction became attenuated over 
time (Beral et al 2008). The authors concluded that the OCPs have 
prevented about 200,000 ovarian cancers and 100,000 ovarian cancer 
deaths since they were introduced a little over 50 years ago. 
 
2.3.9  Dietary factors including vitamins 
 
The effect of dietary habits on ovarian cancer may be direct (as viewed in 
terms of individual nutrients, described below) or indirect through its 
influence on total energy intake viz a viz obesity.  Evidence is accruing that 
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obesity may be positively associated with risk of ovarian cancer. A recent 
pooled analysis of twelve studies observed that obese pre-menopausal, but 
not post-menopausal women had 72% increased risk of ovarian cancer 
compared to women with normal BMI, though BMI in early adulthood was 
not associated with increased risks of ovarian cancer (Schouten  et al 2008).  
 
Less proven is the impact of dietary habits and individual nutrients in ovarian 
cancer prevention. Fruits and vegetables contain bio-active substances that 
have cancer-prevention potentials. While high levels of fruits and vegetable 
consumption have been associated with reduced risk of some cancers, the 
same can not be said of ovarian cancer. A pooled analysis of cohort studies 
found no evidence to suggest that fruits and vegetables can offer protection 
against ovarian cancer (Koushik et al 2005).  
 
Most of the prospective studies examining the associations between 
vitamins A, C, E and specific carotenoids have yielded negative overall 
results. In the Nurses Health Study with 301 invasive ovarian cancer cases, 
intake of vitamins A, C, E and other carotenoids from food or supplements 
was not associated with reduced risk of ovarian cancer (Fairfield et al 2001). 
The authors, however, noted that a high total intake of fruits and vegetables 
during adolescence was associated with a reduced risk of ovarian cancer. 
Similar null associations were observed in the Women’s Health Initiative 
study, a cohort study in Canada (Thomson et al 2008, Navarro Silvera et al 
2006). A pooled analysis of ten prospective studies did not observe that the 
major carotenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein 
and lycopene) had any protective effect on ovarian cancer risk (Koushik et al 
2006). Nevertheless, Tung K-H and colleagues observed that vitamin A and 
beta-carotene, but not the other anti-oxidants had modest protective effects 
on ovarian cancer risk, especially of the mucinous type (Tung et al 2005).  
 
While there appears to be very weak or no inverse relationship between 
folate and related nutrients on ovarian cancer risk, there are suggestions 
that high folate intake may be protective against ovarian cancer mainly 
among women who consume alcohol (Larsson et al 2004, Navarro Silvera et 
al 2006, Tworogger et al 2006).  
 
2.4  Vitamin D 
 
Ever since vitamin D was discovered by Edward Mellamby in 1919 
(Mellamby 1919) during his investigation into the causes of rickets, many 
new insights into its roles in disease prevention have emerged. Vitamin D is 
a family of compounds consisting of 9,10 secosteroids which differ in their 
side-chain structures (Mehta and Mehta 2002). Secosteroids have the same 
cyclopentanoperhydrophenanthrene ring structure as steroids but in 
secosteroids, two B-ring carbon atoms (C-9 and 10) out of the four steroid 
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rings are not joined giving it a “broken ring” appearance (Norman 2008, 
Deeb et al 2007).  
 
There are five forms of vitamin D; vitamin D2, ergosterol; D3, cholecalciferol; 
D4, 22,23 dihydroergoalciferol; D5 sitosterol (24-ethylcholecalciferol) and D6 
stigmasterol (Napoli et al 1979). The two main forms of vitamin D are vitamin 
D3, which is formed in the skin after exposure to sunlight or ultraviolet light 
and vitamin D2, which is obtained by irradiation of a few plant materials or 
food (DeLuca 2004, Holick and Garabedian 2006, Lips P 2006). Vitamin D 
does not naturally exist in significant quantities in the human food chain, 
because evolutionally humans have evolved a photosynthetic mechanism in 
their skin to produce large quantities of vitamin D3 (Hollis 2005). 
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Figure 5. Activation of vitamin D illustrating the structures of both 
forms of the vitamin: cholecalciferol (D3) and ergocalciferol (D2) 
Zerwekh 2004;41;272-281 
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2.4.1  Synthesis and metabolism 
 
The generation of vitamin D3 starts in the skin after exposure to ultraviolet B 
(UVB) irradiation within the wavelength range of 290-315nm (Holick et al 
1980). In animals, 7-dehydrocholesterol (7-DHC, also called pro-vitamin D) 
is synthesized de novo in the skin from Acetyl CoA via multiple steps 
(Glossmann 2010). Pro-vitamin D is distributed throughout the epidermis 
and dermis but is most abundant in the stratum spinosum and stratum 
basale.   
 
When the skin is exposed to UVB within the range of 290-315nm, 7-DHC is 
photolytically converted to pre-vitamin D3 (Holick et al 1980). Pre-vitamin D3 
is then non-enzymatically converted to vitamin D3 in a heat-dependent 
process i.e. the higher the temperature, the larger the amount of pre-vitamin 
D3 that isomerizes into vitamin D3 (WHO/IARC 2008). In order to regulate 
vitamin D3 production and prevent intoxication, pre-vitamin D3 is also 
converted to lumesterols, tachysterols and other inactive photoproducts such 
as suprasterols (Holick 1981, MacLaughlin 1982, Webb et al 1989). The 
conversion of pro-vitamin D to pre-vitamin D3 is very rapid, taking place in 
seconds while the isomerisation of pre-vitamin D3 to vitamin D3 can take 
hours (Tian et al 1993), hence circulating vitamin D concentrations are at 
their maximum level within 12-24 hours after UVB exposure (Adams et al 
1982, Chen et al 2007).  
 
Vitamin D3 and vitamin D2 obtained from diet are subsequently incorporated 
into chylomicrons and transported by the lymphatic system into the venous 
circulation (Holick 2007). Within the circulation, vitamin D (vitamin D3 and 
vitamin D2 are in this context referred to jointly as vitamin D) is bound to 
vitamin D-binding protein (VDBP) which transports it to the liver where it is 
converted to 25-hydroxyvitamin D (25-OHD) by the 25-hydroxylase enzyme. 
This is the major circulating form of vitamin D; it has a long-half life, and can 
be used to determine vitamin D status (Holick 2007, WHO/IARC 2008). 
However, 25-OHD is inert by itself and needs to be converted to the 
hormone1α,25-dihydroxyvitamin D (1α,25-(OH)2D) by 1α-hydroxylase and 
the candidate hormone, 24,25-dihydroxyvitamin D (24R,25-(OH)2D3 by 24-
hydroxylase enzyme in the kidney, under the action of parathyroid hormone, 
before it becomes biologically active (Fraser and Kodicek 1970, Dusso et al 
2005, Norman 2008).  
 
Compared to 25-OHD whose half-life is in weeks, that of 1α,25-(OH)2D is in 
hours and its plasma concentrations are 1000-fold less than those of 25-
OHD (Mullin and Dobbs 2007). Apart from its short half-life, 1α,25-(OH)2D 
can not be used to determine vitamin D status  because its serum levels will 
be normal or may even be elevated in deficiency states because of 
secondary hyperthyroidism (Hollick 2007). The 1α,25-(OH)2D generated in 
the kidney is secreted into the circulation, bound to VBDP, and then 
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transported to target organs, where it induces genomic and non-genomic 
responses through its interaction with the vitamin D receptor (VDR) (Norman 
2008, Prentice et al 2008).  
 
The main target organs of 1α,25-(OH)2D  are the intestine, bone, parathyroid 
glands and the kidney itself, where it participates in the maintenance of 
calcium and phosphorus homeostasis. Initially, it was thought that 
hydroxylation of 25-OHD to 1α,25-(OH)2D occurs only in the kidney but since 
1981, it has been discovered that many extra-renal tissues posses the 
1α,25-(OH)2D enzyme and can produce 1α,25-(OH)2D from 25-OHD 
(Barbour et al 1981, Bises et al 2004, Norman 2008). The locally produced 
1α,25-(OH)2D generates biological responses in these tissues, does not spill 
into circulation and therefore has very little effect on plasma 1α,25-(OH)2D 
concentrations (Norman 2008, Prentice 2008). The regulation of 1α-
hydroxylase at extra-renal sites is different from that of the kidney enzyme. 
At extra-renal sites, the regulation is mainly under the control of local factors 
such as cytokines and growth factors, which act to optimize local levels of 
1,25-(OH)2D (Dusso et al 2005). 
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Figure 6. Vitamin D metabolism. Reprinted from Deeb KK, Trump DL 
and Johnson CS. Vitamin D signalling pathways in cancer: potential for 
anticancer therapeutics Nature Rev Cancer 2007 with permission from 
Nature publishing group 
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2.4.2  Determinants of vitamin D production  
 
Cutaneous synthesis of vitamin D within the UVB range of 290-315 nm 
accounts for most of an individual’s nutritional requirements (Holick 2006). 
Thus, factors that affect cutaneous synthesis play important roles in 
maintaining vitamin D equilibrium and vitamin D status of an individual. 
These factors can be extrinsic and intrinsic  
 
(i) Season; ultraviolet radiation is a function of its solar zenith angles (SZA) 
which is the angle between the local vertical and the position of the sun at 
any given time (Webb 2006, Kimlin 2008). All year long, the SZA changes 
because of the earth’s rotation around the sun.  During summer, the SZA’s 
are small implying that the sun is more overhead and able to deliver more 
ultraviolet rays compared to winter when the SZAs are very large and 
oblique resulting in lower ultraviolet rays (Webb AR 2006, Kimlin 2008). Also, 
a UVB irradiation threshold of 18 mJ/cm2 is required to induce vitamin D 
production (Matsuoka 1989), a level not reached during winter in northern 
areas (Hollis 2005). 
 
(ii) latitude; at latitudes below 35o, the solar zenith angle is very direct and 
cutaneous vitamin D production can occur all year long but at latitudes 
above 35o, the SZA is very oblique during the winter months so that almost 
all the UVB photons below 315 nm are absorbed by the ozone layer 
preventing any cutaneous vitamin D production [Hollick 2004]. The higher 
the altitude, the longer the period when vitamin D can not be produced in the 
skin during winter (Kimlin 2008). Likewise, at lower altitudes, UVB travels 
through less atmosphere and particles and is thus more effective in 
generating vitamin D production. 
 
(iii) Time of the day; UVB is mainly present in sunlight between 10am and 
3pm (Holick 2004, Kimlin 2008). (iv) Air pollution, particulate matter within 
the atmosphere will reduce UVB levels while snow and sand reflect UVB 
(Webb 2006, Kimlin 2008). 
 
(v) Skin pigmentation; melanin pigment competes for and absorbs UVB 
photons responsible for the photolysis of 7-DHC to pre-vitamin D3 (Clemens 
et al 1982). While this is a positive adaptive mechanism for dark skinned 
people living in tropical countries, it becomes a problem when they live in 
northern countries as they become liable to vitamin D deficiency. Also, the 
conversion rate of 7-DHC to pre-vitamin D3 is much slower in dark skinned 
people compared to light skinned people. While a light skinned individual will 
produce maximal pre-vitamin D3 with 10 minutes of exposure in a strong 
summer sun, a dark skinned individual will require almost 1 hour. A dark 
skinned person requires 5-10 times longer exposure to sunlight to produce 
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the same amount of vitamin D3 as a light skinned person (Clemens et al 
1982). 
 
Other factors include (vi) Age; elderly people are less exposed to sunshine, 
have less vitamin D3 precursors in their skin due to age-related changes in 
skin composition and the decline in renal function associated with ageing 
may also contribute (Holick et al 1989, Slovik et al 1981). (vii) Obesity, which 
is associated with low serum vitamin D levels and this is thought to be due to 
excessive storage of vitamin D metabolites in fat tissues leading to non-
release into circulation (Parikh et al 2004, Wortsman et al 2000, Hypponen 
and Power 2007). (vii) Gender; women generally have lower serum vitamin 
D levels because of their higher amount of body fat (van Dam RM, 
Hypponen and Power 2007), moreover, people with (viii) fat malabsorption 
are prone to having low vitamin D levels (Haderslev 2003,  WHO/IARC 
2008). 
 
2.4.3  Rate limiting steps in production 
 
Because vitamin D is toxic at high doses, its production is in a state of 
continuous equilibrium in order to optimise plasma concentrations. In light 
skinned individuals, 7-DHC preferentially converts to inactive isomers, 
lumisterol and tachysterol, rather than pre-vitamin D3 after more than ten 
minutes exposure to UVB but as soon as pre-vitamin D3 stores are depleted, 
exposure of lumisterol and tachysterol to UVB encourages 
photoisomerisation of these isomers back to pre-vitamin D3 (Holick 1981, 
MacLaughlin 1982). This implies that less than 15% of all 7-DHC undergoing 
photoisomerisation at any single point in time will be converted to pre-
vitamin D3 (WHO/IARC 2008). Likewise, after adequate amounts of vitamin 
D3 have been formed, continuous exposure of the skin to sunlight causes its 
rapid degradation into many inactive products such as transvitamin D, 
suprasterols 1 and suprasterols 2 (Webb et al 1989). According to 
calculations made in Boston, USA, during summer, 1 and 3 hrs of exposure 
to sunlight resulted in 75% and 95% vitamin D3 photodegradation 
respectively. Thus prolonged exposure to sunlight does not cause linear 
increases in vitamin D production (Webb et al, 1989).    
 
Within the circulation, the most important limiting factor is the regulation of 
1α,25-(OH)2D production (Norman 2008). Serum calcium, phosphorus, 
fibroblast growth factor 23 (FGF-23) can either upregulate or downregulate 
1α,25-(OH)2D production depending on need. Likewise, 1α,25-(OH)2D can 
decrease its own synthesis through negative feedback by decreasing the 
synthesis and secretion of PTH form the pituitary gland and by increasing 
the expression of 24-hydroxylase (24-OHase) enzyme (Dusso et al 2004, 
Henry 2005, Holick 2007, Deeb et al 2007). The 24-OHase enzyme 
catalyzes a series of oxidation reactions at carbons 24 and 23 leading to a 
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side chain cleavage and inactivation to the biologically inactive calcitroic acid 
(Dusso et al 2004, Deeb et 2007). Mice lacking a functional 24-hydroxylase 
gene have high serum 1,25(OH)2D levels due to the decreased capacity to 
degrade it (St.-Arnaud et al 1996). Likewise, 24-OHase is regulated in a 
reciprocal manner by 1α-OHase (Dusso et al 2004).  
 
2.4.4  Vitamin D from diet  
 
Vitamin D is not a vitamin in the true sense because it is formed in the body.  
Very few food substances contain vitamin D. The best dietary sources of 
vitamin D3 are fresh oily fish. Abundant vitamin D3 sources include wild 
salmon and cod-liver oil, fresh, farmed or canned salmon, sardines, 
mackerel, herring and tuna fish (Bouillon 2001, Holick 2007, Lips 2006, 
Chen et al 2007). The major sources of vitamin D2 are mushrooms (e.g. 
Shiitake, Oyster, chanterelles etc). When Shiitake mushroom is sun-dried, 
the vitamin D2 content is 15 times more than the fresh type (Hollick 2007). In 
many western countries, milk, yoghurts, butter, margarine, cheese, cereals, 
orange juice and infant formulas are fortified with vitamin D3 but these are 
very small, usually 100IU/8 oz compared to the 600-1000IU/3.5 oz present in 
fresh, wild salmon (Hollick 2007). 
 
2.4.5  Concepts of vitamin D deficiency, insufficiency and sufficiency 
 
Serum 25-OHD concentrations are used in determining vitamin D status. 
Previously, vitamin D deficiency was defined as serum 25-OHD level less 
than 25 nmol/L because clinical evidence of skeletal diseases (rickets or 
osteomalacia) become manifest below this level (Wolpowitz and Gilchrest 
2006). Because of emerging information on the myriad of vitamin D actions, 
definition of vitamin D deficiency has extended beyond its relationship with 
skeletal health alone. In vitamin D literature, the term deficiency is gradually 
being replaced by insufficiency. Vitamin D insufficiency is defined as the 
serum vitamin D level associated with adverse health outcomes within the 
population. This corresponds to a serum 25-OHD level of ≤ 50 nmol/L 
(Malabanan et al 1998, Hollick 2006, Bischoff-Ferrari et al 2006).  
 
Physiologically, the threshold for vitamin D sufficiency is the maximum 
serum 25-OHD level beyond which no association exists between further 
increases in serum 25-OHD level and further decreases in serum PTH 
(Wolpowitz and Gilchrest 2006). In essence, this refers to the 25-OHD level 
needed for maximal suppression of PTH, which has been variously 
estimated to be between 70 and 80 nmol/L (Thomas et al 1998, Chapuy et al 
1997, Heaney et al 2003). An expert consensus, however, has adopted a 
serum 25-OHD level of 75 nmol/L to indicate vitamin D sufficiency (Dawson-
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Hughes et al 2005, Bischoff-Ferrari et al 2006). Serum 25-OHD levels 
between 52 and 72 nmol/L are considered as relative insufficiency (Holick 
2007). Since intake of 1 mcg/day of vitamin D increases the serum 25-OHD 
concentrations by about 1 nmol/L (Heaney et al 2003), it is estimated that a 
daily vitamin D intake between 800 IU and 1500 IU (20 mcg and 37.5 mcg) 
is necessary to attain and maintain sufficient serum vitamin D concentrations 
but the requirements will be higher in people with circumstances which 
already predispose to vitamin D deficiency (Hollick 2007, Vieth 2004). In 
perspective, in many countries, 1liter of milk contains only 100 IU of vitamin 
D which will only increase plasma 25-OHD concentrations by between 2-3 
nmol/L.  
 
2.4.6. Vitamin D Receptor  
 
Vitamin D receptor (VDR) is a nuclear receptor that modulates the biological 
activities of the active form of vitamin D. The VDR gene is located on 
chromosome 12q12q14p and is made up of promoter and regulatory regions 
and exons, spanning 75kb, which encode domains of the full length VDR 
protein (Haussler et al 1998, WHO/IARC 2008).  
 
The VDR protein is made up of 3 regions; the NH2-terminal region 
containing a ligand-independent transactivation function, the central region 
contains the DNA binding domain, which targets the VDRE receptors, and 
the C-terminal region, which contains the ligand binding domain and RXR 
heterodimerization motif (Deeb et al 2007). The ligand binding domain is 
responsible for the high-affinity binding of 1,25(OH)2D. After ligand binding, 
conformational changes occur in the VDR structure (Dusso et al 2004).  
 
The vitamin D-VDR complex heterodimerizes with retinoid X receptors 
(RXR), but before it can become active, it needs to be translocated to the 
nucleus, where it modulates transcription by binding to specific DNA 
elements in the promoter regions of the vitamin D response elements (VDRE) 
(Cheskis and Freedman 1994, Prufer et al 2000). Co-activators such as 
steroid receptor coactivator (SRC) and Creb binding protein 300 (CBP300), 
which modify chromatin enzymatic activities or histone acetylase activities 
play important roles in VDR mediated transcription (Wang 2009). VDR was 
initially thought to be involved only in calcaemic regulation, but recent 
studies have discovered that it is also involved in regulating cell proliferation, 
differentiation and immunodulation. It is ubiquitous and present in many 
tissues and cells within the body, but at different concentrations (Nagpal et al 
2005, Bouillon et al 2006).  
 
The VDR can modulate the expression of VDREs in three ways (Nagpal et al 
2005): (i) by positively regulating the expression of specific genes by binding 
to the VDREs in their promoter regions (Sutton and MacDonald 2003, 
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Pinette et al 2003), (ii) by negatively regulating the expression of other 
genes by binding to negative VDREs (Liu et al 1996, Dong et al 2003) (iii) 
inhibiting gene expression by antagonizing the activities of some 
transcription factors (Alroy et al 1995, Nagpal et al 2005). It is estimated that 
the VDR directly regulates the expression of about 200 genes which include 
osteocalcin, osteopontin, carbonic anhydrase II, calbidin, interleukins 2 and 
12, tumour necrosis factor-a, p21, p27 (Lomri and Baron 1992, Quelo 1998; 
D’Ambrosio et al 1998, Tobler 1987, Nagpal et al 2005) and may indirectly 
regulate another 300 genes (Carlberg 2003).  
 
Many polymorphisms of the VDR gene occur with considerable differences 
between races but the most commonly encountered polymorphisms, FokI, 
BsmI, ApaI and TaqI are found in the intron separating exon VIII and IX 
(Morrison et al 1994, Dusso et al 2004). The polymorphisms may be 
synonymous (Bsml, Apal, Taql and Tru9l) and non-synonymous (Fokl) (Deeb 
et al 2007). The functional effects of these polymorphisms are not very clear 
but e.g. when Fokl polymorphism occurs at translation initiation, the result is 
a smaller VDR with greater transcriptional activity than the full length VDR 
(Deeb et al 2007). 
 
2.4.7  Mechanisms of action of vitamin D 
2.4.7.1  Genomic actions  
 
Vitamin D generates biological responses by regulating gene expression 
after binding to the VDR (Deeb et al 2007). The VDR is a steroid hormone 
receptor which regulates gene expression in a ligand-dependent manner 
(Evans 1988). Formation of the ligand-receptor complex results in 
conformational changes in the receptor protein, which allows the complex to 
interact with specificity with other proteins that participate in the transcription 
process (Norman 2008). The anti-proliferative effects of vitamin D are 
mediated through the genomic pathways (Ylikomi et al 2002). Genomic 
actions of vitamin D take place over a long period of time; maybe even days 
(Wang 2009).  
 
2.4.7.2  Non-genomic actions  
 
Non-genomic actions mediated by vitamin D are very rapid, usually 
occurring in minutes and do not require transcription. They are mediated 
through the initiation of many signal transduction systems including calcium 
influx, calcium release from intracellular stores, modulation of adenylate 
cyclase, phospholipase C, protein C kinase pathways (Lehmann and Meurer 
2010). The VDR and 1α,25-(OH)2D-membrane-associated rapid response 
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steroid binding protein (1α,25-(OH)2D-MARRS) modulate the non-genomic 
actions of vitamin D (Dusso et al 2004). The major non-genomic action of 
vitamin D is the rapid intestinal absorption of calcium brought about when vit 
D-VDR complex activates signalling cascades such as protein kinase C 
(PKC) resulting in rapid opening of cellular voltage-gated calcium channels 
ensuring an increase in intracellular calcium (Deeb et al 2007, Dusso et al 
2004).  
 
2.4.8  Clinical functions of vitamin D 
 
The classical function of vitamin D is to maintain adequate serum calcium 
levels and thus, prevent rickets in children and osteomalacia and 
osteoporosis in adults (DeLuca 2004). It does this in three different ways  
(i) it stimulates the active absorption of calcium, together with phosphate in 
the intestine. It is the only hormone known to induce the proteins necessary 
for active calcium absorption in the intestine (DeLuca 2004),  
(ii) when intestinal calcium absorption is low or absent due to dietary 
deficiencies, vitamin D mobilizes calcium from skeletal sources by 
stimulating osteoblasts to produce receptor activator nuclear factor- B ligand 
(RANKL) which in turn induces pre-osteoclasts to become mature 
osteoclasts (Suda et al 2002). Mature osteoclasts then cause bone 
resorption by removing calcium and phosphate from bones and making them 
available within the circulation, 
(iii) in the kidneys, vitamin D acts synergistically with PTH to increase the 
reabsorption of calcium from the distal tubules, thereby preventing its 
excretion in urine. 
 
Aside its classical functions, there is increasing evidence that vitamin D may 
be involved in the prevention of some cancers (prostate, breast, colorectal 
and ovaries). The protective effect of vitamin D on breast cancer risk has 
been observed among pre-menopausal and post-menopausal women 
(Abbas et al 2009, Abass et al 2010). While a large study observed that 
vitamin D is important in preventing prostate cancer progression (Li et al 
2007), others have not noted any relationship between serum vitamin D 
levels and prostate cancer risk (Travis et al 2009, Park et al 2010). An 
important similarity in the biology of ovarian, breast and prostate cancer is 
that the three cancers are sex-steroid hormone responsive which underlies 
the possibility of an effect by vitamin D. Vitamin D has also been observed to 
have protective effects in autoimmune diseases such as type 1 diabetes, 
multiple sclerosis, Crohn’s disease, systemic lupus erythematosus, psoriasis, 
and hypertension (Holick 2008, Nagpal et al 2005). It is plausible for vitamin 
D to have this wide range of functions because virtually all tissues and many 
immune cells have a VDR.  
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Likewise, many cells and tissues express the 1α-hydroxylase enzyme, which 
implies that local conversion of 25-OHD to 1α,25-(OH)2D, the active form, 
can take place in such tissues (Holick 2008).  
 
2.4.9. Molecular actions of vitamin D in cancer 
 
1. Antiproliferative effects: Progression through the cell cycle is driven by 
a family of protein kinases mainly the cyclin dependent kinases (CDK) 
and conversely, CDK inhibitors (CDKI) negatively regulate cell cycle 
progression by binding to and suppressing CDK activities (Hunter and 
Pines 1994, Sherr and Roberts 1995). Vitamin D modulates the cyclin 
pathways by regulating the expression of proteins p21 and p27. This 
results in inhibition of CDK, which inhibits cell proliferation by inducing 
G1 cell cycle arrest and withdrawal from cell cycle (Deeb et al 2007, 
Ingraham et al 2008). This is a cellular surveillance mechanism ensuring 
that if problems with DNA replication or repair occur, a cell cycle arrest 
will take place rather than forming aberrant DNA (Deeb et al 2007, 
Ingraham et al 2008). 
 
Vitamin D also regulates the activities of c-myc protooncogene which is a 
cell-cycle related protein that enhances CDK activity through functional 
inactivation of the CDK-inhibitors (Mitchell and El-Deiry 1999, Perez-
Roger et al 1999). Some indirect effects of vitamin D on cell cycle 
regulation such as the upregulation of insulin growth factor binding 
protein 3 (IGFBP3), transforming growth factor- β (TGF- β) and 
downregulation of epidermal growth factor receptor (EGFR) signalling 
pathways also contribute to its antiproliferative effects (Yanagisawa et al 
1999, Huynh et al 1998, Tong et al 1999).  
 
2. Apoptosis: Apoptosis is programmed cell death, and disruptions in 
apoptotic pathways whereby damaged cells keep proliferating, 
accumulating mutations and evading destructions are major hallmarks of 
cancer cells (Ingraham et al 2008). Mutations to the p53 gene which 
discontinues cell cycle when there is DNA damage is found in more than 
half of all cancers (Ingraham et al 2008). Vitamin D regulates key 
mediators of apoptosis by inducing the expression of pro-apoptotic 
proteins such as Bax, Bad and Bak and suppressing the expression of 
anti-apoptotic proteins such as Bcl2 and Bcl-x (Ylikomi et al 2002, Deeb 
et al 2007). It can also induce apoptosis indirectly by increasing 
intracellular calcium levels thereby activating calcium-dependent pro-
apoptotic caspase 12 and micocalpain (Mathiasen et al 2002). Various 
apoptotic mechanisms may however be involved in different cancer cells 
as seen in ovarian cancer cells, where vitamin D also induces apoptosis 
by down-regulating telomerase activity.  
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3. Angiogenesis: Loss of contact inhibition is seen early in many cancers 
(Muehlemann et al 2005). The cell-adhesion molecule, E-cadherin is 
essential for maintaining a polar conformation in epithelial cells and its 
activity can be regulated by vitamin D (Gniadecki et al 1997, Palmer et al 
2001, Ingraham et al 2008). The E-cadherin gene is a tumour 
suppressor gene commonly absent in transformed cells and an 
indication of poor prognosis in colon cancer cells (Palmer et al 2001). 
Experimentally, high concentrations of vitamin D and its analogs 
decrease the invasiveness, inhibit angiogenesis and metastases of 
different cancer cell lines. In cultured malignant cells, vitamin D analogs 
can also down-regulate cell-invasion associated matrix 
metalloproteinases 2, 9 and serine proteinases (Mantell et al 2000, Koli 
and Keski-Oja 2000). 
 
2.4.10  Vitamin D and ovarian cancer 
2.4.10.1  Ecological studies 
 
The first reports of a possible association between vitamin D and ovarian 
cancer were reported in ecological studies using sunlight as a proxy for 
vitamin D status. The studies observed higher ovarian cancer mortality rates 
among women living at higher altitudes compared to those living at lower 
altitudes (Decarli and La Vecchia 1986, Leftkowitz and Garland 1994). 
Leftkowitz and Garland reported that ovarian cancer mortality was inversely 
proportional to annual intensity of sunlight, and therefore suggested that 
sunlight may be protective against death from ovarian cancer.  More recent 
studies in different parts of the world have, however, yielded varying results. 
While a worldwide study and two studies conducted in the USA observed 
inverse correlations between UVB and ovarian cancer mortality (Freedman 
et al 2002, Grant 2006, Grant and Garland 2006), one from Spain and 
another from Japan did not observe such inverse correlation (Mizoue 2004, 
Grant 2007). However, using ovarian cancer mortality rather than incidence 
may have inherent bias and not really reveal the association between 
sunlight and ovarian cancer because of arbitrary and iatrogenic differences 
in cancer survival in different geographical areas. Moreover, using mortality, 
rather than incidence does not distinguish between the effects of 
sunlight/UVB on preventing ovarian cancer and improving survival from 
ovarian cancer (Porojnicu et al 2007). 
 
Nevertheless, ecological studies of ovarian cancer incidence and sunlight 
have also been contradictory. A study making use of data from 175 countries 
observed that the age-adjusted ovarian cancer incidence rates were highest 
in countries located at higher altitudes (Garland et al 2006). The study also 
noted that while UVB irradiance was inversely associated with ovarian 
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cancer, stratospheric ozone which reduces UVB transmission was positively 
associated with ovarian cancer. However, two other multinational studies did 
not observe any inverse relationship between ovarian cancer incidence and 
sunlight (Waltz and Chodick 2008, Tuohimaa et al 2007) despite the fact that 
one of them observed an inverse association between sunlight and some 
other cancers (Tuohimaa et al 2007). 
  
2.4.10.2  Dietary studies 
 
Dietary studies of the association between vitamin D and ovarian cancer 
have not yielded consistent results. The dietary studies have used food 
frequency questionnaires to determine the vitamin D content of different food 
substances. In a case-control study in Mexico, Salazar-Martinez and 
colleagues reported a 57% lower risk of ovarian cancer among women 
whose diet contained the highest amount of vitamin D compared to those 
with the lowest (Salazar-Martinez et al 2002). Even though the risk reduction 
was smaller in a similar study in Italy, women whose diet contained the 
highest amount of vitamin D still had a 30% reduced risk of ovarian cancer 
compared to those whose diet contained the lowest amounts (Bidoli et al 
2001). On the contrary, four studies conducted in the USA did not observe 
lower risks of ovarian cancer among women who consumed food 
substances high in vitamin D relative to those who consumed less (Kushi et 
al 1999, Goodman et al 2002, Cramer et al 2001, Koralek et al 2006).   
 
Thus from available ecological and dietary studies, no definite inferences 
can be drawn regarding the relationship between vitamin D and ovarian 
cancer. 
 
2.4.10.3  Experimental studies 
 
In vitro studies have shown that 1α,25-(OH)2D can suppress ovarian cancer 
cell growth via various molecular mechanisms.  
 
GADD45 is a p53, BRCA1 regulated nuclear protein that plays a role in cell 
cycle progression, maintenance of genomic stability and DNA repair (Smith 
1996, Jin et al 2000). Jiang and colleagues demonstrated that 1α,25-(OH)2D 
causes cell cycle arrest at the G2/M transition by inducing GADD45 in 
ovarian cancer cells (Jiang 2003). Cell cycle arrest caused by 1α,25-(OH)2D 
induction of GADD45 is  dependent on time, dose and VDR but not on p53.  
 
Li P et al also demonstrated that 1α,25-(OH)2D arrests ovarian cancer cells 
in G1 phase by increasing the accumulation and ensuring stability of the p27 
protein, another known tumour suppressor (Li et al 2004). It achieves this by 
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(i) decreasing the amounts of cyclin E and cyclin E-associated CDK2 activity, 
ultimately resulting in less p27 phosphorylation and (ii) reducing the affinity 
of p27 for Skp2 ubiquitin ligase, the enzyme that causes its degradation 
(Zhang et al 2006).  
 
In normal somatic cells, chromosomal ends (telomeres) undergo progressive 
shortening resulting in irreversible growth arrest but in cancer cells, the 
telomere length is stabilized by the enzyme telomerase (Bodnar et al 1998). 
Abnormally high levels of human telomerase reverse transcriptase (hTERT) 
are expressed in most cancer cells, including ovarian cancers. Vitamin D 
(1α,25-(OH)2D) has been shown to down-regulate hTERT activity in ovarian 
cancer cells (Jiang et al 2004), thereby promoting their capability to induce 
growth arrest.  
 
The study by Miettinen and colleagues offered new insights into the effects 
of vitamin D in ovarian cancer cells (Miettinen et al 2004). Their study 
revealed that high concentrations of 1α,25-(OH)2D (10-100nM) were needed 
to inhibit ovarian cancer cell lines (OVCAR-3 cell lines) and low 
concentrations actually stimulated cell proliferation, similar to results 
obtained with prostate and breast cancer cell lines (Gross et al 1997, Love-
Schimenti et al 1996). The vitamin D analogue, EB1089 (secocalcitol) 
displayed very strong growth inhibition of ovarian cancer cell lines at much 
lower concentrations compared to 1α,25-(OH)2D. Another study has 
confirmed that experimentally, EB1089 suppresses ovarian cancer cell 
growth and activates the GADD45 gene much more effectively than 1α,25-
(OH)2D and in concentrations that do not induce hypercalcaemia (Zhang et 
al 2005). 
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Figure 7. Summary of the current understanding of the molecular 
mechanisms of action of vitamin D in ovarian cancer cells. Reprinted 
from Zhang X, Nicosia SV, Bai W. Vitamin D Receptor is a Novel Drug 
Target for Ovarian Cancer Treatment. Current Cancer Drug Targets 
2006 with permission from Bentham Science publishers.  
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3  AIMS OF THE THESIS 
The major aim of this thesis is to elucidate the relationship between vitamin 
D and ovarian cancer using serial, pre-diagnostic serum vitamin D 
measurements  
Specific objectives are 
 
1. To determine the effect of storage time and sampling season on the 
stability of serum 25-hydroxyvitamin D in serum samples that have been 
stored at -25oC for many years. 
 
2. To investigate the association between serum 25-hydroxyvitamin D and 
ovarian cancer risk and to explore the impact of season of blood 
collection on the risk estimates. 
 
 
3. To evaluate the independent and joint effects of serum 25-
hydroxyvitamin D and serum calcium on ovarian cancer risk. 
 
4. To ascertain whether long term vitamin D status can predict ovarian 
cancer risk. 
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4  MATERIALS AND METHODS 
4.1  Finnish Maternity Cohort (FMC) 
 
The Finnish Maternity Cohort (FMC) was established in 1983 by the National 
Institute for Health and Welfare, THL (formerly National Public Health 
Institute). After an informed consent has been obtained (since 2001), blood 
samples are withdrawn from pregnant women at the municipal maternity 
centres between the 8th and 13th weeks of gestation in order to screen for 
intra uterine infections caused by Treponema pallidum, human 
immunodeficiency virus and hepatitis B virus (Koskela et al 2000, Pukkala et 
al 2007). The informed consent covers the use of the left-over serum 
samples for epidemiological studies and according to the law on KTL, 
samples obtained before 2001 can also be used for such studies. The 
samples are mailed from the municipal maternity centres to the THL’s 
prenatal serology laboratory in Oulu. After routine screening, the left over 
sera are then stored in polypropylene cryo vials at -25 ºC in a well protected 
biorepository in Oulu. The average bench lag time (time between sampling 
and storage) is 4 days (range 1 to 10 days). Other personal data collected 
and registered in the FMC database include personal identity code, parity 
and number of gestations, date of sample collection at both municipal 
maternity centres and at prenatal serology laboratory in Oulu, date of sample 
processing, place or residence at birth and at sample collection.  
 
More than 98% of pregnant women in Finland have donated serum samples 
to the FMC since inception and the biorepository presently contains about 
1.6 million serum samples. Approximately 60,000 new serum samples are 
added to the biorepository every year.  
 
4.2  Finnish Cancer Registry (FCR) 
 
The FCR is nationwide. Cancer registration began in Finland in 1952 and 
since 1953 when the first complete nationwide cancer registration was 
conducted; over 950,000 cancer cases have been registered at the FCR 
(Pukkala 2001). Compulsory notification of all diagnosed or suspected 
cancer cases by physicians, laboratories and hospitals commenced in 1961 
(Pukkala 2001, www.cancer.fi).  The coverage of the FCR is virtually 
complete with no loss to follow-up and for solid tumours; the registration is 
over 99% complete (Teppo et al 1994). The ICD-O-3 coding nomenclature 
which takes into consideration the tumour site, morphology, behaviour and 
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grade has been used by the FCR since 2005. Coding is done by qualified 
secretaries under the supervision of the Registry physician.  
 
Linkage to other registries and database such as the FMC, Statistics Finland 
is done through the use of a unique 11-digit personal identity code 
mandatory to every resident of Finland since 1961. The personal identity 
code is indicated on cancer registry forms. The cancer registry file containing 
personal identity codes is annually matched through computerized linkage 
with the cause of death register at the Statistics Finland so that dates and 
cause of deaths in cancer patients can be added to the FCR records 
(Pukkala 2001). It is also regularly linked with the Central Population 
Register to ensure that the personal identity codes are correct. The FMC 
was linked to the FCR to obtain the cases and controls used in this thesis. 
 
Standards are rigorously maintained to ensure that there is no breach of 
confidentiality and individual data are well protected. In order to use data 
from the FCR for linkage and research purposes, approval needs to be 
obtained from the relevant ethical research committee, THL and other 
pertinent (e.g. data protection) authorities (Pukkala 2001). 
 
4.3  Study population 
 
Study I 
Only first and second pregnancy samples were used for this study. 
Randomly, four women who donated serum samples during their first 
pregnancies were selected every other year between 1984 and 2002 such 
that two women donated serum samples during winter and the other two, 
during summer. The women were matched for age and municipality of 
residence. For this study, we defined winter as 15th December to 15th of 
March while summer was defined as 1st of May to 31st of August. In all, there 
were 201 summer samples and 201 winter samples available for pick up at 
the FMC biorepository. Furthermore, among the selected women, 100 who 
had donated blood samples to the FMC at their second pregnancies, 
provided the second pregnancy occurred within five years of the first, were 
identified. From this 2nd group, 40 women who donated their second 
samples within the same season and another 40 who donated their second 
samples during the opposite season were selected. 
 
Study II 
Two hundred and one ovarian cancer cases diagnosed within ten years of 
serum sampling were randomly selected from the FMC. If a case had 
donated more than 1 serum sample during this 10-year period, the sample 
donated closest to the time of cancer diagnosis was selected. The median 
THL – Research 47/2010 48 
Epidemiological study of the 
role of vitamin D in the 
aetiology of ovarian cancer 
 
time between serum sampling and cancer diagnosis was 5 years. In most 
cases, the histology of the tumour was serous (39%) or mucinous (35.9%) 
ovarian carcinomas.  
 
We matched two different sets of controls that were alive and free of cancer 
at the diagnosis of the index case to each case. While the two sets of 
controls were equally matched to cases for age at sample withdrawal ±1 
year and parity, the first set of controls (2 per case, 398 serum samples 
available) were matched for date of blood sampling ±4 weeks (same season, 
most ideal practice) and the second set of controls were matched for 
opposite season of index blood sampling (1 per case approximately 6 
months apart ±4 weeks, 199 samples available).  
 
Studies III and IV 
After linkage to the FCR, we identified ovarian cancer cases who had 
donated pre-diagnostic serum samples to the FMC on more than one 
occasion, at least one year before cancer diagnosis. We excluded cases 
who had participated in the second study. Thus, we had 172 cases, whose 
histological diagnoses were serous (41%), mucinous (36%) or endometroid 
(9%) ovarian carcinoma.  
 
Controls were women from the FMC who were alive and free of cancer at 
the time of diagnosis of the index case and who had been pregnant/donated 
serum samples on at least two separate occasions. One control per case 
was matched for age at sample withdrawal ± 1 year, (ii) parity, and (iii) date 
of index blood sampling ± 2 weeks for both sets of samples. In essence, we 
had two sets of samples for each case-control pair. A control had to fulfil the 
matching criteria for both sampling periods. 
 
For the 4th study, only cases and controls who donated their paired serum 
samples during the same season were selected leaving 53 case-control 
pairs whose 1st and 2nd samples were donated during winter and 37 case-
control pairs whose 1st and 2nd samples were donated during summer.  
 
4.4  Laboratory methods 
 
All samples were coded before they were sent to the laboratories in order to 
ensure subject anonymity. Laboratory personnel were blinded to case-
control status. Samples from cases and their matched controls were 
arranged sequentially in a random order, analysed with the same batches of 
assay kits and on the same day to minimise assay drift bias.  
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Study I 
For each subject, one set 160 µl aliquots of each sera was sent to the 
departments of Anatomy, University of Tampere, Finland, for 25-OHD 
measurement, and another set was sent to Clinical Chemistry Laboratory, 
University of Umeå, Umeå, Sweden for androstenedione measurement.  
Quantification of 25-OHD was performed using 25-OHD IDS 
radioimmunoassay (IDS Ltd, Boldon UK). The interassay coefficients of 
variation (CV) were 4.0% and 3.9% at 25-OHD concentrations of 26.5 
nmol/L and 103nmol/L respectively. Androstenedione concentrations were 
measured by competitive chemilumiscent enzyme immunoassay (DPC 
Immulite 2000 Androstenedione Chemilumiscent EIA, UK). The interassay 
coefficients of variation were 16.9% at 2.2 ng/ml and 6.2% at 5.2 ng/ml.  
 
Studies II, III and IV 
Measurement of 25-OHD was performed at the Department of Medical 
Biosciences, University of Umeå, Umeå, Sweden using a 25-OHD 
radioimmunoassay (IDS Ltd, Boldon UK). The within, between, and total 
coefficients of variations (CV) of the assay were 7.8%, 9.6% and 12.4% at 
level 28.4 nmol/L 25-OHD, and 4.1%, 7.4% and  8.5% at 107 nmol/L 25-
OHD, respectively. The manufacturer stated a specificity of 100% for 25-
OHD3, 75% for 25-OHD2, 100% for 24, 25-OH2D3, and less than 0.01% or 
0.3% cross-reactivity for cholecalciferol (D3), and ergocalciferol (D2), 
respectively. Quantification of serum calcium was performed at the Clinical 
Chemistry Laboratory, Östersunds Hospital, Östersund, Sweden, using the 
Roche/Hitachi Cobas C system analyzer (Roche Diagnostics GmbH, 
D68298 Mannheim, Germany).  
 
4.5  Statistical methods 
 
All statistical analyses were carried out using SPSS for windows (SPSS Inc., 
Chicago IL). Versions 14 and 15 were used for the first two studies, while 
version 18 was used for the last two studies. In all studies, two-sided p< 0.05 
was considered statistically significant. Descriptive statistics was calculated 
for all the variables in each study; presented as means (standard deviation 
or range) for normally distributed data and median (percentiles) for skewed 
data. Where appropriate, data were log-transformed to reduce departure 
from normal distribution. Correlations were assessed with Pearson 
correlation coefficient. In studies II, III and IV, conditional logistic regression 
was used to calculate the relative risk of ovarian cancer (expressed as odds 
ratio with 95% confidence interval, OR, 95% CI) across the different levels of 
serum 25-OHD concentrations. 
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Study I 
Clustered box plots, stratified for sampling season were drawn to depict the 
relationship between the two hormones and duration of sample storage. We 
used Pearson’s correlation coefficient to test for the correlation between 
duration of sample storage and 25-OHD and androstenedione 
concentrations. The effects of sampling season on single and paired 
hormone measurements were assessed using independent and paired 
sample t-tests respectively.  
 
Study II 
Quintile cut-off points were determined using the 25-OHD distribution among 
the controls, separately for controls with the same season sampling (as 
cases) and for controls with different sampling season (as cases). The 
multivariate model was adjusted for age at last full term pregnancy and 
bench lag time. Secondary analyses were conducted for the main 
histological groups available in the study (serous and mucinous tumours) 
and comparing women with sufficient serum 25-OHD (> 75 nmol/L) 
concentrations to those without. Tests for trend were performed using serum 
25-OHD as a continuous variable.  
 
Study III 
Quartile cut-off points for both 25-OHD and calcium were determined using 
the distribution among the controls. Conditional logistic regression was used 
to calculate odds ratio with 95% confidence interval (OR with 95% CI) for 
ovarian cancer in the different quartiles of 25-OHD and calcium using the 
lowest quartiles as the reference category. Tests for trend were calculated 
using continuous scale of the variables, log-transformed for 25-OHD 
because the overall distribution was slightly skewed even though the season 
specific distributions were normal. The multivariate model was adjusted for 
age at first full term pregnancy and region of residence because they were 
the only variables that affected the risk estimates by more than 5%. 
Secondary analyses were conducted among cases whose lag times to 
cancer diagnosis were more than 3 years and their matched controls and 
among women with sufficient levels of serum 25-OHD compared to those 
with insufficient levels.  
 
To determine the independent and joint effects of the two biomarkers on 
ovarian cancer risk, the women were categorized into four groups based on 
their combined serum 25-OHD and calcium levels (i) Low 25-OHD /low 
calcium - women with both 25-OHD and calcium categories within the 1st 3 
quartiles, i.e. (25-OHD Q1, Q2, Q3 + Calcium Q1, Q2, Q3). This represented 
the reference category, (ii) high 25-OHD/low calcium – women whose 25-
OHD were within the 4th quartile but whose calcium were within the 1st 3 
quartiles (25-OHD Q4 + calcium Q1, Q2, Q3), (iii) low 25-OHD/high calcium 
– women with 25-OHD within the 1st 3 quartiles but calcium within the 4th 
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quartile (25-OHD Q1, Q2, Q3 +calcium Q4), (iv) high 25-OHD/high calcium - 
both 25-OHD and calcium were within the 4th quartiles (25-OHD Q4 + 
calcium Q4). We tested whether calcium modifies the effect of vitamin D in 
ovarian cancer and vice versa. This testing was done with a likelihood ratio 
test to compare two nested models, by considering the difference between 
the model-specific scaled deviances. 
 
Study IV 
Four groups were formed depending on the median 25-OHD concentrations 
for both 1st and 2nd samples. (i) Women whose 25-OHD concentrations were 
below the season-specific median values during both 1st and 2nd sampling 
periods, (ii) women with 25-OHD concentration below the median value 
during the 1st sampling period but above the median value during the 2nd 
sampling periods, (iii) women with 25-OHD concentration above the median 
value during the 1st sampling period but below the median value during the 
2nd sampling period, (iv) women whose 25-OHD concentrations were above 
the median values during the 1st and 2nd sampling periods. The first group 
comprising women with 25-OHD levels below median values during both 1st 
and 2nd sampling period was used as the reference category. The model 
was adjusted for age at first full term pregnancy and region of residence. 
Women who donated their paired samples during winter and those who 
donated their paired samples during summer were analyzed separately. 
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5  RESULTS 
Study I 
Effect of sampling season and storage time on serum 25-OHD and 
androstenedione concentrations 
There was no correlation between serum 25-OHD concentrations and 
storage time for both first (rs = -0.08, p-value = 0.1) and second pregnancy 
samples (rs = -0.09, p-value = 0.5). The results did not differ by season of 
blood donation. The correlations between 25-OHD concentrations and 
storage time for samples donated in summer were 0.00 (p-value 0.98) and -
0.11 (p-value 0.59) for first and second pregnancy samples respectively 
while for winter samples, they were -0.08 (p-value 0.64) and -0.09 (p-value 
0.59) for first and second pregnancy samples respectively.  
 
Similarly, there was no correlation between serum androstenedione 
concentrations and storage time (rs = 0.09). Mean serum 25-OHD 
concentrations were highest in 1992 (44.8 nmol/L, 95% CI 39.2 - 50.5) and 
1994 (44.5 nmol/L, 95% CI 38.8 - 50.2) and lowest in 1996 (34.2 nmol/L, 
95% CI 30.4 – 38.3) and 2002 (34.7 nmol/L 95% CI 30.1 – 39.3). No 
corresponding differences were observed for the serum androstenedione 
levels. 
 
Mean serum 25-OHD concentrations were significantly higher during 
summer compared to winter for both the first (44 nmol/L vs 33.4 nmol/L, p 
≤0.001) and the second (51.6 nmol/L vs 39.8 nmol/L, p ≤0.001) pregnancy 
samples over all the years investigated. Conversely, androstenedione levels 
appeared to be higher in winter compared to summer but the difference in 
the mean levels was of borderline significance, mean difference µd= 0.3 
nmol/ml, 95% CI 0.0-0.6; p-value = 0.05).  
 
 
Among women who donated two samples, individual serum 25-OHD 
concentrations were significantly higher during summer compared to winter 
irrespective of pregnancy order. Also the mean 25-OHD concentrations for 
winter-winter sample combinations were significantly lower compared to 
other sample combinations such as summer-summer and summer-winter 
combinations. No corresponding differences were observed for 
androstenedione.  
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Figure 8.  Mean 25-hydrovitamin D concentrations (± 2 standard errors) 
by season of blood donation from every two years from1984 to 2002 
 
 
 
Study II 
Association between serum 25-OHD concentrations and ovarian cancer 
risk  
The median lag time between serum sampling and cancer diagnosis was 5 
years. Among cases and controls that were tightly matched season of blood 
donation, low serum 25-OHD concentration was associated with an 
increased risk of ovarian cancer. Women with insufficient serum 25-OHD 
concentrations (< 75 nmol/L) were at borderline increased risk of ovarian 
cancer compared to women with sufficient serum concentrations, OR 2.7, 
95% CI 1.0-7.9). The odds ratio, OR, comparing women within the lowest to 
highest quintile of serum 25-OHD concentration was 1.8, (95% CI 0.9-3.5, p-
trend = 0.26). Among women who were matched for opposite season of 
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blood donation (6 months ±4 weeks), no differences in risk estimates were 
observed comparing the extreme quintiles: odds ratio 1.1 (95% CI 0.6-2.2, p-
trend = 0.49). Analyses were carried out among the two most prevalent 
histological types of ovarian cancer in the study (serous and mucinous). 
Comparing lowest to highest quintiles, the OR for serous tumours was 1.4 
(95% CI 0.7-3.2) and 1.5 (95% CI 0.4-3.1) for mucinous tumours 
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Study III 
Relationship between serum 25-OHD, calcium concentrations and the 
risk of ovarian cancer  
There was no correlation between serum 25-OHD and serum calcium 
concentrations among cases and controls. Even though the season matched 
mean serum 25-OHD levels were higher among controls compared to cases 
for all the seasons, the differences in the mean levels were not statistically 
significant. The highest difference in the mean levels was observed during 
spring (8.5nmol/L).  
 
Adjusting for age at first pregnancy and region of residence, women within 
the highest fourth of serum 25-OHD concentrations tended to have reduced 
risk of ovarian cancer compared to women within the lowest fourth but the 
trend test was not statistically significant (OR 0.57 95% CI 0.26–1.24; P-
trend = 0.07). The odds ratio reduced further and the trend test became 
statistically significant when cases with lag time less than 3 years were 
excluded from the analysis (OR 0.43, 95% CI 0.18-1.05, P-trend = 0.02). 
Women with sufficient 25-OHD concentrations (>75 nmol/l) had a 
significantly reduced risk of ovarian cancer compared to those with 
insufficient serum concentrations (OR 0.32; 95% CI 0.12-0.91, p-value 0.03). 
 
Women within the highest quartile of serum calcium had significantly 
reduced risk of ovarian cancer compared to those within the lowest quartile; 
OR 0.41 (95% CI 0.19–0.85, P-trend = 0.004). Exclusion of cases with lag 
time less than 3 years had no material effect on the point estimate; OR 0.37 
(95% CI 0.16-0.85, P-trend 0.002). 
 
We sought evidence of multiplicative interaction between calcium and 
vitamin D. Compared to women who had low calcium/low 25-OHD 
concentrations, those who had high calcium/high 25-OHD levels had an 
odds ratio of 0.26 (95% CI 0.07-0.90). We, however, observed no evidence 
to suggest that calcium modifies the effect of vitamin D (p = 0.25) or vitamin 
D modifies the effect of calcium (p = 0.12) on ovarian cancer risk 
THL – Research 47/2010                57 Epidemiological study of the 
     role of vitamin D in the 
     aetiology of ovarian cancer
 
59
 
Ta
bl
e 
2.
  
R
el
at
iv
e 
ris
k 
(e
st
im
at
ed
 a
s 
od
ds
 r
at
io
, 
O
R
, 
w
ith
 9
5%
 c
on
fid
en
ce
 i
nt
er
va
ls
, 
C
I) 
of
 o
va
ria
n 
ca
nc
er
 b
y 
qu
ar
til
e 
of
 s
er
um
 2
5-
hy
dr
ox
yv
ita
m
in
 D
 a
nd
 c
al
ci
um
 c
on
ce
nt
ra
tio
ns
 a
m
on
g 
Fi
nn
is
h 
w
om
en
 fo
llo
w
ed
 u
p 
to
 1
3 
ye
ar
s 
af
te
r s
am
pl
e 
do
na
tio
n 
 
Se
rum
 25
-O
HD
 co
nc
en
tra
tio
ns
 
   
 Qu
art
ile
 1 
 Qu
art
ile 
2 
 Qu
art
ile 
3 
 Qu
art
ile 
4 
 P-t
ren
d 
 Q4
 vs
 Q
1-3
 
 Qu
art
ile
 va
lue
s, 
nm
ol/
L 
 <3
1.5
 
 31
.5–
40
.0 
 40
.1–
57
.7 
 ≥5
7.8
 
 
 
 Ca
se
s/c
on
tro
l, n
1  
 42
/43
 
 44
/44
 
 52
/42
 
 30
/43
 
 
 
 
 
  
  
  
 
 
OR
, a
dju
ste
d2  
1.0
 (re
fer
en
ce
) 
1.0
1 (
0.5
4–
1.8
7) 
1.1
3(0
.60
–2
.12
) 
0.5
7(0
.26
–1
.24
) 
0.0
7 
0.5
4(0
.28
–1
.02
) 
 Ex
clu
din
g c
as
es
  w
ho
 do
na
ted
 se
rum
 sa
mp
les
 w
ith
in 
1 t
o 3
 ye
ars
 of
 ca
nc
er 
dia
gn
os
is 
 
  Qu
art
ile
 va
lue
s 
 <3
2.0
 
 32
.1-
40
.5 
 40
.6-
58
.1 
 ≥5
8.2
 
 
 
 Ca
se
s/c
on
tro
l, n
 
 36
/33
 
 37
/33
 
 35
/35
 
 25
/36
 
 
 
 OR
, a
dju
ste
d2 
 1.0
 (re
fer
en
ce
) 
 0.9
3 (
0.4
8-1
.82
) 
 0.7
9 (
0.3
9-1
.63
) 
 0.4
3 (
0.1
8-1
.05
) 
 0.0
2 
 0.4
9 (
0.2
4-1
.01
) 
 
Se
rum
 ca
lciu
m 
co
nc
en
tra
tio
ns
 
 Qu
art
ile
 va
lue
s,m
mo
l/L
 
 <2
.2 
 2.2
–2
.4 
 2.4
–2
.6 
 ≥2
.6 
 
 
 Ca
se
s/c
on
tro
l, n
1  
 46
/39
 
 50
/45
 
 48
/44
 
 26
/44
 
 
 
 
 
 
 
 
 
 
 
60
 
OR
 
1.0
(re
fer
en
ce
) 
0.9
9(0
.54
–1
.85
) 
0.8
6(0
.46
–1
.60
) 
0.4
6(0
.23
–0
.95
) 
0.0
05
 
 OR
, a
dju
ste
d2  
 1.0
(re
fer
en
ce
) 
 1.0
4(0
.55
–1
.96
) 
 0.8
4(0
.44
–1
.61
) 
 0.4
1(0
.19
–0
.85
) 
 0.0
04
 
 
 Ex
clu
din
g c
as
es
  w
ho
 do
na
ted
 se
rum
 sa
mp
les
 w
ith
in 
1 t
o 3
 ye
ars
 of
 ca
nc
er 
dia
gn
os
is 
 
  Qu
art
ile 
va
lue
s 
 <2
.2 
 2.2
-2.
4 
 2.4
-2.
6 
 
 
 
 Ca
se
s/c
on
tro
l, n
 
 35
/31
 
 43
/35
 
 37
/32
 
 20
/39
 
 
 
 OR
, a
dju
ste
d2 
 
 1.0
 (re
fer
en
ce
) 
 1.2
6 (
0.5
9-2
.67
) 
 0.9
7 (
0.4
6-2
.08
) 
 0.3
7 (
0.1
6-0
.85
) 
 0.0
02
 
 
 1 C
on
tro
ls w
ere
 m
atc
he
d f
or 
ag
e a
t s
eru
m 
sa
mp
ling
, p
ari
ty 
an
d d
ate
 of
 bl
oo
d d
on
ati
on
 (±
 2 
we
ek
s) 
2 A
dju
ste
d f
or 
ag
e a
t fi
rst
 fu
ll te
rm
 pr
eg
na
nc
y a
nd
 re
gio
n o
f re
sid
en
ce
THL – Research 47/2010                58 Epidemiological study of the 
     role of vitamin D in the 
     aetiology of ovarian cancer
 
61
 
 Ta
bl
e 
3.
  J
oi
nt
 e
ffe
ct
 o
f s
er
um
 2
5-
hy
dr
ox
yv
ita
m
in
 D
 a
nd
 c
al
ci
um
 o
n 
th
e 
re
la
tiv
e 
ris
k 
 
(e
st
im
at
ed
 a
s 
od
ds
 ra
tio
, O
R
,  
w
ith
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
s,
 C
I) 
of
 o
va
ria
n 
ca
nc
er
 a
m
on
g 
 
Fi
nn
is
h 
w
om
en
  
  
 Gr
ou
p 1
 
 Gr
ou
p 2
 
 Gr
ou
p 3
 
 Gr
ou
p 4
 
 Ca
se
/co
ntr
ol,
 n 
 11
6/9
6 
 26
/32
 
 21
/33
 
 5/1
1 
 OR
, a
dju
ste
d1  
 1.0
 (re
fer
en
ce
) 
 0.5
1 (
0.2
9–
1.0
5) 
 0.4
1(0
.19
–0
.87
) 
 0.2
6(0
.07
–0
.90
) 
 Ex
clu
din
g c
as
es
 w
ith
 la
g t
im
es
 > 
3 y
ea
rs 
 
 Ca
se
/co
ntr
ol,
 n 
 
92
/73
 
21
/25
 
16
/28
 
4/1
1 
OR
, a
dju
ste
d1 
 
1.0
 (re
fer
en
ce
) 
0.4
7 (
0.2
0—
1.0
9) 
0.3
4 (
0.1
4 -
0.8
1) 
0.1
9 (
0.0
5 –
 0.
77
) 
 Gr
ou
p 1
- L
ow
 vit
am
in 
D/L
ow
 ca
lciu
m 
 
Gr
ou
p 2
 - H
igh
 vit
am
in 
D/L
ow
 ca
lciu
m 
 
Gr
ou
p 3
 - L
ow
 vit
am
in 
D/H
igh
 ca
lciu
m 
 
Gr
ou
p 4
 - H
igh
 vit
am
in 
D/H
igh
 ca
lciu
m 
1 A
dju
ste
d f
or 
ag
e a
t fi
rst
 fu
ll te
rm
 pr
eg
na
nc
y a
nd
 re
gio
n o
f re
sid
en
ce
 
   
THL – Research 47/2010 59 
Epidemiological study of the 
role of vitamin D in the 
aetiology of ovarian cancer 
 
Study IV 
Long term vitamin D status and the risk of ovarian cancer risk in a 
longitudinal study 
The average time difference between 1st and 2nd sample donation was 2.6 
years. For controls, the correlation between 1st and 2nd sample serum 25-
OHD concentrations was highly significant for summer combinations (rs = 
0.60 (p-value ≤ 0.001) and moderately significant for winter combinations (rs 
= 0.39, p-value = 0.004). This was, however, not true for the cases: the 
correlation was 0.25 (p-value = 0.14) for summer combinations and 0.16 (p-
value = 0.28) for winter combinations. For the matched summer pairs, 
controls had higher mean serum 25-OHD concentrations for both the first 
and second serum samples as compared to cases (55.4 vs 45.4 nmol/L for 
1st samples and 57.4 vs 49.6 nmol/L for 2nd samples). This was not true for 
the matched winter pairs (37.7 vs 40.9 nmol/L for 1st samples and 37.8 vs 
36.9 nmol/L for 2nd samples).  
 
Among women who donated their two serum samples during summer 
season, having both serum 25-OHD concentrations above the median 
values compared to having serum 25-OHD levels below the median values 
was associated with an inverse risk of ovarian cancer, OR 0.21 (95% CI 
0.05-0.99). A protective effect of increasing serum 25-OHD levels against 
ovarian cancer did, however, not reach statistical significance (p-trend = 
0.06). Any over time effects were not observed among women who donated 
their two serum samples during winter.  
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6  DISCUSSION 
In the following, we will discuss the limitations and strengths of our study 
setting and design, and how the new findings fit into the literature on the role 
of vitamin D in ovarian cancer 
 
6.1   Use of biobank material and determination of serum 25- 
  hydroxyvitamin D and androstenedione 
 
Our observations that there was no correlation between the serum 25-OHD 
concentrations and the length of time the serum samples have been stored 
for is similar to other studies. Ocke et al (1994) had earlier observed very 
high correlation (rs = 0.81) between the serum 25-OHD concentrations of the 
same individual measured 4 years apart. This was recently confirmed by 
Jorde et al (2010) who reported similar correlation coefficient (rs = 0.80) 
between the serum 25-OHD concentrations of the same individual measured 
1 year apart. The correlation coefficients for samples stored over a longer 
period of time, 14 years, however ranged between 0.42 and 0.52. Another 
recent study has observed that serum 25-OHD has excellent reproducibility 
with an intraclass correlation coefficient of 0.72 over a 3 year period 
(Kotsopoulos et al 2010). Bodnar et al used another method to determine 
the stability of serum 25-OHD in stored blood. They compared 25-OHD 
concentrations using two very important predictors of serum 25-OHD 
(season and race) in sera frozen for more that 40 years to those frozen for 2 
years among pregnant women. Serum 25-OHD concentrations were 
significantly higher in summer samples compared to winter samples, and 
among white women compared to black women, irrespective of the time the 
samples were donated (Bodnar et al 2009) implying that long term storage 
had no deleterious effect on the validity of serum 25-OHD measurements in 
epidemiological studies.  
 
Serum 25-OHD has also been noted to withstand multiple freeze-thaw 
cycles (Antoniucci et al 2004, Wielders and Wjnjberg 2008, Lewis and Elder 
2008), and is not degraded under ambient room or outdoor temperature for 
up to 8 days as long as the sample is protected from direct sunlight (Lewis 
and Elder 2008). It is thought that the reason why vitamin D and its 
metabolites are very stable in serum/plasma is because they are completely 
bound to the vitamin D binding protein and the complex formed can 
withstand insults effectively (Hollis 2008).  
 
The seasonal differences in serum 25-OHD concentrations we reported are 
one of the most consistent features of vitamin D metabolism and have been 
reported several times (Stamp and Round 1974, Lu  et al 1992, Harris and 
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Dawson-Hughes 1998, Ono et al 2005). No previous studies had, however, 
explored the use of paired samples to investigate seasonal differences in 
serum 25-OHD concentrations. Our observation that paired samples taken 
during winter/winter had significantly lower serum 25-OHD levels compared 
to other seasonal combinations such as summer/summer and 
summer/winter is an indication that epidemiological studies making use of 
paired samples to investigate vitamin D status/disease associations must 
appropriately match the paired samples of cases and controls for seasonality. 
 
There is no reason to believe that early pregnancy would have affected the 
serum 25-OHD concentrations and, by extension, measurements. It has 
been shown that early pregnancy serum 25-OHD concentrations remained 
constant and is within the pre-pregnancy range (Bruinse and van den Berg 
1995). However, as pregnancy progresses longitudinally, there may be 
changes in serum 25-OHD levels which are mainly reflections of the different 
seasons a pregnancy traverses and the accompanying seasonal changes 
rather than inherent changes brought about by pregnancy. If exposure to 
sunlight and vitamin D intake are taken into consideration, 25-OHD 
concentrations in pregnancy reflect the non-pregnant state (Ardawi et al 
1997). This was buttressed in our study where we observed no correlation 
between serum 25-OHD concentrations and number of days of gestation. 
Thus, first trimester serum 25-OHD level is representative of a woman’s 25-
OHD level.   
 
Quantification of serum 25-OHD is the most clinically useful assessment of 
vitamin D status because its long half-life (3 weeks) provides an indication of 
vitamin D stores obtained from both UV radiation and long-term dietary 
intake. Likewise, the production of 25-OHD is primarily substrate dependent 
and there is very little regulation in the liver. Unlike 25-OHD, the 
physiologically active form of vitamin D, 1,25-OHD2, is not clinically useful in 
determining an individual’s vitamin D status because it has a very short half-
life (4-6 hours) coupled with the fact that its enzymatic conversion in the 
kidneys is very tightly regulated. In clinical practice, serum 1,25-OHD2 
measurement is mainly used as a confirmatory test of some disorders of the 
vitamin D endocrine system such as pseudo-vitamin D deficiency rickets and 
hereditary 1,25-OHD2 resistant rickets (Zerwekh 2004). 
 
Serum 25-OHD measurement encompasses both 25-hydroxycholecalciferol 
(25-OHD3) and 25-hydroxyergocalciferol (25-OHD2). Previously, both forms 
of 25-OHD used to be measured and reported separately because it was 
believed that this will distinguish the sunlight derived from the dietary derived 
form but since food is now fortified with both forms of 25-OHD and both 
forms are used in multivitamin supplements, the need to distinguish the two 
forms in measurement is no longer necessary. It is still important to note that 
total 25-OHD measured and reported in laboratories is made up mainly of 
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25-OHD3, with 25-OHD2 contributing only minimally, and as many as 99% 
of individuals in USA may have no circulating 25-OHD2 (Hollis 2008). 
 
6.2  Serum 25-OHD concentrations and the risk of ovarian  
       cancer 
 
Our observation of a non-statistically significant increased risk of ovarian 
cancer among women with the lowest serum 25-OHD levels compared to 
those with the highest is similar to that reported by three other studies that 
have investigated this relationship (Tworoger et al 2007, Arslan et al 2009, 
Zheng et al 2010). Apart from the study by Arslan et al, the other 2 studies, 
however, observed that circulating 25-OHD appeared to be protective 
among certain subgroups: among overweight women (Tworoger et al 2007, 
Zheng et al 2010) and among women with sufficient plasma levels compared 
to those with insufficient plasma levels (Tworoger et al 2007). We also noted 
a borderline increased risk of ovarian cancer among women with insufficient 
serum 25-OHD concentrations compared to those with sufficient serum 
concentrations but we did not have the BMI data on this subset of cohort 
members to explore the effect of BMI on the relationship between 25-OHD 
and ovarian cancer risk. Overall, the results from our study support previous 
findings.  
 
One similarity between all these studies is their prospective nature. Serum 
25-OHD concentrations were determined in blood samples donated before 
cancer diagnosis. While two of the studies were nested case-control studies 
(Arslan et al 2009, Toriola et al 2009), the other two were pooled studies 
combining resources from 3 cohorts (Tworoger et al 2007) and 7 cohorts 
(Zheng et al 2010). The age at blood donation, however, differed markedly 
between pre-menopausal women in our cohort and the combined pre and 
post-menopausal women in the other studies, (median ages at blood 
donation; 31.5 years vs 51 to 58 years).  
 
While all the studies appropriately matched controls to cases based on 
season, our study differs from other studies because, we further assessed 
the effects of improper matching for season on the results by matching 
another set of controls who donated serum samples at seasons different to 
the cases (6 months ± 4 weeks). We observed an attenuation of the relative 
risks in analysis carried out using these set of controls demonstrating the 
impact of proper seasonal matching in vitamin D and associated disease 
studies. 
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6.3  Independent and joint effects of calcium and 25-OHD on  
       ovarian cancer risk 
 
To the best of our knowledge, this study was the first to investigate an 
association and joint effects of serum calcium and 25-OHD with regard to 
ovarian cancer risk. Our observation of a strong inverse association between 
serum calcium and ovarian cancer is novel and intriguing. Previous studies 
on the relationship between calcium and ovarian cancer risk had employed 
the use of dietary calcium and have yielded conflicting results. Goodman et 
al (2002) reported significant inverse associations between both dietary and 
diary calcium intake and ovarian cancer risk but not with non-dairy calcium 
intake. Likewise, the use of calcium supplements appeared to be associated 
with a reduced risk of ovarian cancer. Bidoli and colleagues also reported a 
30% significant risk reduction in ovarian cancer risk among women with the 
highest dietary calcium intake compared to those with the lowest (Bidoli et al 
2001) while Koralek and colleagues observed borderline inverse 
associations between dietary calcium intake and ovarian cancer risk 
(Koralek et al 2006). Nevertheless, other studies, including a pooled analysis 
of cohort studies have not observed any protective effect for calcium on 
ovarian cancer risk, be it calcium from dietary or dairy sources (Kushi et al 
1999, Genkinger et al 2006, Park Y et al 2009).  
 
Serum calcium is the most ideal way to determine an individual’s calcium 
levels and relating serum calcium, rather than dietary calcium to ovarian 
cancer risk represents the best way to determine the relationship between 
calcium and ovarian cancer. The reason is that despite the fact that diet is 
one of the major means of obtaining serum calcium, it has been observed 
that dietary calcium intake has no significant effect on serum calcium levels 
(Jorde et al 2001) because serum calcium level is a function of vitamin D, 
parathyroid hormone (PTH) levels, and other dietary factors (Nordin 2000, 
Jorde et al 2001, Steingrimsdottir 2005).  In a diet containing 20 mmol of 
calcium, about 16 mmol are lost in faeces indicating that only 4 mmol are 
absorbed through the intestine (Ramasamy 2006).  
 
Calcium may reduce ovarian cancer risk by mediating apoptosis, cell growth 
and proliferation (McConkey and Orrenius 1997, Ramasamy 2006) and 
down-regulating the production of PTH, a suspected tumour-promoter and 
mitogenic factor (McCarty 2000). The effects of vitamin D and calcium on 
disease processes may be synergistic with VDR and CaR signalling 
pathways converging on the same pathway (Peterlik et al 2009). The joint 
effect of vitamin D and calcium has been demonstrated with regards to colon, 
breast and some other cancers (Cho et al 2004; Sergeev 2004, Lappe et al 
2007). A previous study had investigated the joint effects of calcium and 
lactose, but not calcium and vitamin D in ovarian cancer (Goodman et al 
2002). The study noted an inverse association between calcium intake and 
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ovarian cancer which was modified by lactose intake wherein high calcium 
intake was beneficial among women with low lactose intake but not among 
women with high lactose intake. 
 
Similar to other studies, (Tworoger et al 2007, Toriola et al 2009, Arslan et al 
2009, Zheng et al 2010) we observed in our joint effect study a non-
statistically significant reduction in ovarian cancer risk among women within 
the highest quartile of serum 25-OHD levels compared to those within the 
lowest quartile but in contrast to other studies, we noted that women with the 
highest serum 25-OHD levels had a borderline reduced risk of ovarian 
cancer compared to other all other women. Women with sufficient serum 25-
OHD levels also had significantly reduced risk of ovarian cancer compared 
to women with insufficient levels; previous studies having reported borderline 
inverse associations (Tworoger et al 2007, Toriola et al 2009). 
  
Both 25-OHD and calcium, however, acted independently and do not modify 
the effect of each other on ovarian cancer risk.  
 
6.4  Long term vitamin D status and ovarian cancer risk 
 
An acknowledged weakness in previous studies on the association between 
vitamin D status and ovarian cancer is the use of only one time serum 25-
OHD concentrations in the determination of ovarian cancer risk. We 
attempted to overcome this in our study. In healthy individuals, serum 25-
OHD concentrations do not change drastically over time (Jorde et al 2010, 
Hofmann  et al 2010, Kotsopoulos 2010) except when measured in different 
seasons (Agborsangaya et al 2010). Therefore, long term vitamin D status 
as determined by at least 2 serum 25-OHD measurements taken from the 
same individual, years apart, is likely to reflect the individual’s long term 
serum 25-OHD status and changes in the status.  
 
In this study, cancer free women devoid of any cancer at the time when 
ovarian cancer diagnosis was made in the cases exhibited significant 
tracking in their serum 25-OHD concentrations during summer. A reduced 
risk of ovarian cancer was observed among women with consistently high 
serum 25-OHD concentrations during summer, suggesting deterioration of 
vitamin D status from continuously high/sufficient serum 25-OHD levels is a 
risk factor for the development of ovarian cancer. An experimental study has 
shown that while high concentrations of 1,25-OHD2 (100nM) inhibited 
growth of ovarian cancer cell lines, concentrations of 1nM had no effect on 
cell growth and 0.1nM stimulated cell growth underscoring the importance of 
always having high serum 25-OHD concentrations. Among those who 
donated their serum samples during winter, mean serum 25-OHD levels for 
cases and controls were very low which may have precluded our ability to 
observe any differences in risk. 
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6.5  Pathobiology of vitamin D, vitamin D receptor and ovarian  
       cancer 
 
Studies on polymorphisms in VDR gene and the risk of ovarian cancer also 
support the role of the vitamin D endocrine system in ovarian carcinogenesis.  
The VDR is present in both normal and malignant ovarian cells where it 
mediates the actions of vitamin D (Bouillon et al 1995, Ahonen et al 2000). 
 
Lurie et al (2008) noted diverse patterns in ovarian cancer risk associated 
with VDR gene polymorphisms across different ethnic groups. Caucasian 
but not Japanese women who were heterozygous for the FokI f allele had 
increased risk of ovarian cancer compared with homozygous carriers. 
Likewise, while Caucasian women, who were heterozygous and 
homozygous ApaI A allele carriers were at increased risk of ovarian cancer 
compared with homozygous carriers of the ApaI a allele, Japanese women 
were not. The increased risk of ovarian cancer associated with the FokI 
genotype is functionally and biologically coherent because the f allele has an 
earlier start codon giving rise to a protein with three extra amino acids which 
has a lower transactivation of VDR target genes compared to the F allele 
(Jurutka et al 2000).  
 
On the other hand, Japanese women who were heterozygotic carriers of the 
Cdx-2 A allele had reduced risks of ovarian cancer compared with the 
homozygotic G allele carriers. The Cdx-2 G→A SNP alters the binding site of 
CDX transcription factor, and the A allele binds more efficiently resulting in 
higher VDR activity (Yamamoto et al 1999, Uitterlinden et al 2004).  
 
The above results have been replicated in a larger study whereby the FokI 
genotype was associated with increased risk of ovarian cancer and the Cdx-
2 had no effect on risk among Caucasian women (Tworoger et al 2009).  
 
Not only are VDR polymorphisms associated with risk of developing ovarian 
cancer, they are also associated with improved prognosis in patients with 
ovarian cancer (Tamez et al 2009). In stage I ovarian cancer, there was no 
difference in survival between women with C/C, C/T and T/T genotypes. But 
in stages II-IV cancers, 84% of women with C/C genotype were alive 30 
months post surgery compared to 50% of patients with C/T and T/T 
genotypes (Tamez et al 2009), suggesting that the C/C genotype conferred 
some survival advantages compared to the others. 
 
THL – Research 47/2010 67 
Epidemiological study of the 
role of vitamin D in the 
aetiology of ovarian cancer 
 
6.6  Limitations of the study 
 
The following limitations of our study need to be taken into consideration. 
The use of oral contraceptives is a confounder of the relationship between 
serum 25-OHD concentrations and ovarian cancer risk because oral 
contraceptives increase serum 25-OHD concentrations (Harris and Dawson-
Hughes 1998) and at the same time, protect against ovarian cancer. We did 
not have information on oral contraceptive use in our cohort but we presume 
the women would have been off OCP use for many weeks before the 
samples were taken, since the samples were taken between the 8th and 
13th weeks of gestation. In other studies that have controlled for OCP use, 
including OCP in the model did not have any appreciable effects on the risk 
estimates. Hence, the possibility of oral contraceptive use being a 
confounder in this scenario may be slight but cannot be discarded. 
 
A significant interaction has been observed between 25-OHD concentrations 
and BMI  (Zheng et al 2010) and two studies have observed reduced risks of 
ovarian cancer among overweight women with high serum 25-OHD levels 
(Tworoger et al 2007, Zheng et al 2010) . We however did not have 
information on BMI in this subset of women within the FMC to investigate the 
effect of BMI on the relationship between serum 25-OHD levels and ovarian 
cancer risk.  
 
Our study included only fertile, pre-menopausal women; hence we may not 
be able to generalize the results obtained from our study to infertile and 
post-menopausal women. Nevertheless, Pukkala and colleagues (Pukkala et 
al 2007) reported similar cancer incidence rates among women in the FMC 
compared to the general population, except for some tumours such as 
borderline tumours of the ovary, whose incidence rate is lower among 
women in the cohort compared to the general population.  
 
In the 3rd study, we measured total calcium rather than ionized calcium. It is 
believed that ionized calcium, rather than total calcium may provide the best 
indication of an individual’s calcium status because it is the biologically 
active form and is tightly regulated by calcium-regulating hormones 
(Almquist et al 2007). Total calcium levels depend to a large extent on serum 
albumin levels and conditions that may affect serum albumin levels may 
affect total calcium levels. A recent study on serum calcium and breast 
cancer however observed that adjusting for serum albumin levels did not 
substantially change the risk estimates (Almquist et al 2010). Barring any 
conditions that may affect serum albumin levels, total calcium is a good 
indicator of calcium homeostasis.  
 
Our study was not large enough to accommodate extensive sub-group 
analysis. Likewise, the relatively small sample size precluded us from fully 
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investigating the relationship between serum 25-OHD concentrations and 
the various ovarian cancer histological subtypes since the relationship 
between serum 25-OHD concentrations and ovarian cancer will most likely 
differ by histological subtype because vitamin D is identical to the sex-steroid 
hormones and the hormonal risk factors for ovarian cancer differ according 
to histological subtype. This is especially true for the 3rd study where we 
could not investigate the possibility of calcium modifying the effect of vitamin 
D among the various histological subtypes and in the 4th study where we 
could not determine the risk of ovarian cancer among the various histological 
subgroups by long term serum 25-OHD concentrations.   
 
6.7  Strengths of the study 
 
Unlike ecological studies which related ovarian cancer risk to UVB exposure 
and other measures of sunlight, we determined the association between 
vitamin D and ovarian cancer using serum 25-OHD measurements in a 
longitudinal setting applying a prospective nested case-control design with 
serials samples. This is the best way to determine the individual’s vitamin D 
status. The results from ecology studies are not adequate to determine the 
true nature of a relationship between vitamin D and ovarian cancer. Ecology 
studies are mainly good for deriving hypothesis but not for determining 
causalities. This is because ecological studies can only make inferences 
about populations since they do not reflect biological events at the individual 
level (Greenland S and Robins 1985). Furthermore, ecological studies have 
limited statistical prowess to measure the true relationship between 
exposure and outcome and confounding factors can not be entirely 
controlled (Waltz and Chodick 2008). 
 
Our study design was prospective whereby the serum samples had been 
collected before cancer diagnosis thereby ensuring that the serum 25-OHD 
and calcium measurements are more likely to represent the pre-cancer state, 
rather than the peri or post-cancer state. The distinction between the use of 
pre-cancer and post-cancer serum samples to measure serum 25-OHD 
concentrations is very important since the effects of cancer on serum 25-
OHD concentrations are not well known, and the possibility that ovarian 
cancer may have an affect on serum 25-OHD levels can not be ruled out. If 
the samples had been taken after cancer diagnosis, there would have been 
no way to determine if the associations observed were due to the effects of 
ovarian cancer on serum 25-OHD measurements, rather than vice versa. 
Furthermore, in the 2nd and 3rd studies, we conducted secondary analyses 
excluding women who donated serum samples within 2 to 3 years of cancer 
diagnosis in order to eliminate cases who may have had occult ovarian 
cancers and the results were not dissimilar to that obtained in the overall 
analysis. In addition, incident density sampling of cancer free controls and 
their serial samples enabled us to make inferences about the changes in 
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vitamin D status in relation to ovarian cancer risk. Overall, by making the 
study prospective in nature, the risk of inverse causation bias was greatly 
minimized.  
 
The study was nested within the FMC ensuring that cases and controls were 
chosen from the same well-defined source population which greatly reduces 
the possibility of selection bias. Controls subjects were randomly selected, 
alive and free of ovarian cancer at the time of diagnosis of the index case 
and were tightly matched to cases on the basis of risk factors such as parity, 
age and season of blood donation all of which can distort the relationship 
between serum 25-OHD concentration and the risk of ovarian cancer if not 
properly controlled. The population-based nature of the FMC (encompassing 
98% of all pregnant Finnish women, Pukkala E 2007) also offers 
fundamental strength to our study. 
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7  CONCLUSIONS 
From this nested case-control study on vitamin D and ovarian cancer, we 
can draw the following conclusions 
 
1. Serum samples, stored at -25oC in biobanks for upwards of 24 years, 
can be used to study vitamin D-disease associations because 25-OHD is 
stable in stored blood. Such studies must, however, match tightly for 
season of blood donation. 
 
2. We found no overall association between serum 25-OHD concentrations 
and ovarian cancer risk but, we found evidence suggestive of an 
increased risk of ovarian cancer among women with insufficient serum 
25-OHD concentrations compared to those with sufficient serum 
concentrations. Our results further underscored the need to tightly match 
for seasonality because there was evidence of bias in analysis involving 
samples not properly matched for season. 
 
3. Vitamin D and calcium are independently protective against ovarian 
cancer. While increasing serum calcium concentrations were associated 
with a significantly reduced risk of ovarian cancer, increasing serum 25-
OHD concentrations were associated with a borderline reduced risk of 
ovarian cancer. Women with sufficient serum 25-OHD concentrations 
had a significantly reduced risk of ovarian cancer compared to women 
with insufficient serum concentrations.  
 
4. Over time vitamin D status may be the key to protection against ovarian 
cancer. In analysis carried out using two samples collected years apart 
from each woman, having consistently high serum 25-OHD levels during 
summer was associated with a decreased risk of ovarian cancer. No 
similar observations were, however, observed among women who 
donated serum samples during winter.  
 
An important implication for future research is the need for a larger study 
using serial samples to determine the association between changes in 
vitamin D status and ovarian cancer risk.   
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Knowledge of the stability of serum samples stored in large
biobanks is pivotal for reliable assessment of hormone-dependent
disease risks. We studied the effects of sample storage time and
season of serum sampling on the stability of 25-hydroxy vitamin D
(25-OHD) and androstenedione in a stratified random sample of
402 women, using paired sera from the Finnish Maternity Cohort.
Serum samples selected were donated between 6 and 24 yr ago.
The storage time did not affect serum 25-OHD and androstene-
dione levels. However, there was a significant mean difference in
the 25-OHD levels of sera withdrawn during winter (first sample)
vs. during summer (second sample; –18.4 nmol/l, P≤ 0.001). Also
at the individual level, there were significant differences in average
25-OHD levels between individuals with the paired sera taken at
winter–winter compared with other alternatives (summer–winter,
winter–summer, and summer–summer). The androstenedione lev-
els showed no such differences. Long-term storage does not affect
serum 25-OHD and androstenedione levels, but sampling season
is an important determinant of 25-OHD levels. Stored serum sam-
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ples can be used to study disease associations with both hormones.
However, sampling season needs to be taken into account for 25-
OHD by considering matching and stratification and, if possible,
serial sampling.
INTRODUCTION
Vitamin D is a “steroid-like” hormone, which is produced
photochemically from 7-dehydrocholesterol on exposure of the
skin to ultraviolet (UV) light. It can also be obtained from
foods such as cod liver oil, salmon, eggs, liver, and so forth.
Pre-vitamin D exists in 2 forms, ergocalciferol (vitamin D2,
from plant sources) and cholecalciferol (vitamin D3, from an-
imal sources). Once absorbed, vitamin D3 undergoes hydrox-
ylation in the liver to form 25-hydroxyvitamin (OH) D3 (25-
OHD3, which is further hydroxylated to 1,25-dihydroxyvitamin
D3 (1,25 OH2D3) in the kidney, breast, colon, and prostate (1,2).
The traditional function of 25-OHD is to maintain skeletal in-
tegrity by regulating calcium and phosphorus homeostasis (3,4).
Epidemiological studies have associated low serum 25-OHD
levels with a wide variety of diseases such as diabetes, some
cancers, asthma, multiple sclerosis, rheumatoid arthritis, car-
diovascular diseases, and schizophrenia (5).
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Because of the wide range of genomic and nongenomic ef-
fects of 25-OHD and its metabolites, a number of studies are
being conducted exploring the 25-OHD disease associations.
Most of these studies have exploited serum samples that have
been stored in biobanks for several years, even decades. Stored
serum 25-OHD is unaffected by multiple freeze-thaw cycles (6)
and is stable when stored at –20◦C for at least 3 yr (7). The im-
pact of longer storage time has not been thoroughly considered.
However, a recent study reported that maternal sera frozen for
40 yr could be used to detect seasonal and racial differences in
25-OHD concentrations (8). The serum 25-OHD concentrations
in the 40-yr-old sera were, however, lower than those of 2-yr-old
sera.
Androstenedione is a steroid hormone produced from the
adrenals and ovaries. It is primarily synthesized from dehy-
droepiandrosterone (DHEA) and later reversibly converted to
testosterone (9). Previous studies to determine seasonal changes
in androgen levels have been equivocal (10–13).
The action of 25-OHD is androgen dependent in some organs
such as the prostrate (14,15). An experimental study revealed
that in intact animals, prostatic growth was significantly in-
hibited by 25-OHD3, but in castrated animals who have low
androgens, 25-OHD had no effect on prostatic growth (16). At
physiologic concentrations, 25-OHD3 exhibits strong antipro-
liferative activity only in the presence of dihydrotestosterone
(14).
Using paired serum samples that have been stored for periods
ranging from between 6 to 24 yr at the Finnish Maternity Co-
hort (FMC), we sought to determine the effects of storage time
and sampling season on serum 25-OHD and androstenedione
concentrations.
MATERIAL AND METHODS
FMC
The FMC contains 1.3 million first trimester serum samples
from approximately 98% of all pregnant Finnish women. The
samples have been collected since 1983. The samples are col-
lected at municipal maternity care units following an informed
consent during the first trimester of pregnancy for screening of
congenital infections. After the screening tests have been done,
the remaining sample (1–3 ml volume of serum) is stored at
–25◦C in polypropylene cryo vials at the National Institute for
Health and Welfare (formerly National Public Health Institute)
in Oulu, Finland (17). Detailed demographic and reproductive
history data are collected for each participant.
Sample Identification
The samples used for this study were randomly selected fol-
lowing the sampling applied in a previous study within the FMC
(18). In that study, 10 random first pregnancy samples were re-
trieved for every other year from 1984 to 2002 (altogether 100
samples). For this study, we selected 4 comparable first preg-
nancy samples taking into account also the sampling season: two
samples for the same season (summer) and two for the opposite
season (winter), age (+/– 4 yr), and postal code (municipality).
We defined winter as the 15th of December to the 15th of March
and summer as the 1st of May to the 31st of August. A total of
453 eligible individuals were identified from the FMC database.
Of the corresponding 453 samples, eventually 402 samples were
selected to make 201 summer samples and 201 winter samples
appropriately matched for postal code and age. The lowest num-
bers of samples were from 1988 (37), and the highest numbers
were from 1990, 1992, and 1996, with 42 samples each. From
the final list of the 402 individuals, 100 individuals who had
a second pregnancy within 5 yr of the first pregnancy were
identified. We randomly selected 40 such individuals whose
first and second pregnancies were from the same season (sum-
mer/summer and winter/winter) and 40 such individuals whose
first and second pregnancy samples were from different seasons
(summer/winter and winter/summer). Complete paired sample
sets were available for 78 individuals.
Sample Handling
The available, previously unthawed samples were aliquoted
into two 160 µl aliquots for 25-OHD and androstenedione anal-
ysis. Samples with indication of hemolysis or visual signs of
freeze drying were not eligible. One aliquot per sample was
sent to the Department of Anatomy, University of Tampere,
Tampere, Finland, for 25-OHD analysis and another aliquot to
the Clinical Chemistry Laboratory, Department of Medical Bio-
sciences, Umea˚ University, Umea˚, Sweden, for androstenedione
analysis.
Laboratory Methods
Quantification of 25-OHD was done using an 25-OHD IDS-
radioimmunoassay from IDS Ltd (Boldon, UK. The manufac-
turer stated a specificity (% cross-reactivity) of 100% for 25-
OHD3; 75% for 25-OHD2; 100% for 24, 25-OH2D3; and less
than 0.01% or 0.3% for cholecalciferol (D3) and ergocalciferol
(D2), respectively. The mean interassay CV was 4.0% for the first
pregnancy samples and 3.4% for the second pregnancy samples
at 25-OHD mean of 26.5 nmol/l and 103 nmol/l, respectively.
Determination of serum levels of androstenedione were per-
formed at the Department of Medical Biosciences, University
of Umea˚, Umea˚, Sweden. The steroid levels were measured
by competitive chemiluminescent enzyme immunoassay (DPC
Immulite 2000 Androstenedione Chemiluminescent EIA, UK).
With control sera, the interassay CV was 16.9% at 2.2 ng/ml
and 6.2% at 5.4 ng/ml.
The study was approved by the ethical committee of the
National Institute for Health and Welfare, Finland.
Statistical Methods
We used SPSS (SPSS, Inc., Chicago, IL) version 14 for
all statistical analysis. Serum 25-OHD was not normally
D
o
w
n
l
o
a
d
e
d
 
B
y
:
 
[
N
a
t
i
o
n
a
l
 
P
u
b
l
i
c
 
H
e
a
l
t
h
 
I
n
s
t
i
t
u
t
e
]
 
A
t
:
 
0
8
:
5
2
 
1
1
 
J
a
n
u
a
r
y
 
2
0
1
0
STABILITY OF SERUM 25-HYDROXY VITAMIN D AND ANDROSTENEDIONE 53
TABLE 1
Baseline characteristics of a stratified, random sample of women stemming from the Finnish Maternity Cohort with single
and paired pregnancy samples
1st Pregnancy Samples 1st and 2nd Pregnancy Samples
Variable Winter Summer Winter Summer
Number (N) 163 161 38 40
Mean age (yr) 28.6 28.7 30.8 31.2
Mean storage time (yr) 14.9 14.9 13.2 12.3
distributed, and we performed a logarithmic transformation.
Serum androstenedione was normally distributed. Clustered
box plots were drawn for both and the duration of sample
storage, stratified by sampling season. Pearson’s partial
correlation coefficient (r) was used to test for correlation
between duration of sample storage and both 25-OHD and
androstenedione. Independent sample t-test was used to assess
the effect of sampling season on single hormone measurement,
whereas paired sample t-test was used to assess the effect of
the sampling season on paired hormone measurements.
RESULTS
The baseline characteristics (mean age, sample storage time)
of the women who donated one or two pregnancy serum sam-
ples in different seasons were similar. For the first pregnancy
samples, the mean and median ages at sample withdrawal were
28.7 and 29 yr, respectively (range= 22–38 yr). Mean duration
of storage was 14.9 yr, ranging from 6 yr to 24 yr. For the second
pregnancy samples, the mean and median ages were 31.0 and
30.4 yr, respectively (range = 25–40 yr). Their mean duration
of storage was 12.8 yr, ranging from 4 to 22 yr (Table 1).
FIG. 1. Serum 25-hydroxy vitamin D (25-OHD; nmol/l) in a stratified, random sample of pregnant women (n = 402) stemming from the Finnish Maternity
Cohort (1984–2002) by sampling season. The median serum 25-OHD levels are significantly higher in summer than in winter. The error bars represent the 25th
(lower) and 75th (upper) percentiles.
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FIG. 2. Serum androstenedione (ng/ml) in a stratified, random sample of pregnant women stemming from the Finnish Maternity Cohort (1984–2002) by
sampling season. The median serum androstenedione levels appear to be higher in winter than in summer. The error bars represent the 25th (lower) and 75th
(upper) percentiles.
The highest average levels of serum 25-OHD were found
in 1992 [44.8 nmol/l, 95% CI = 39.2–50.5) and 1994 (44.5
nmol/l, 95% CI = 38.8–50.2) and the lowest in 1996 (34.2
nmol/l, 95% CI = 30.4–38.0) and 2002 samples (34.7 nmol/l,
95% CI = 30.1–39.3). For the first pregnancy samples, mean
serum 25-OHD levels were significantly lower in winter than
in summer; 33.4 nmol/l (95% CI = 31.5–35.3) vs. 44.0 nmol/l
(95% CI = 41.4–46.5; P ≤ 0.001), respectively. This was true
also for the second pregnancy samples; 39.8 nmol/l (95% CI =
46.7–56.5) vs. 51.6 nmol/l (95% CI = 34.5–45.0; P ≤ 0.001),
respectively. When stratified by the sampling season, the average
annual serum 25-OHDlevels were lower in the winter than in
the summer (Figs. 1 and 2). The mean androstenedione levels
appeared to be higher in winter than in summer (mean difference
µd = 0.3 nmol/ml, 95% CI = 0.0–0.6; P value = 0.05).
Serum 25-OHD levels showed practically no correlation with
storage time for the first pregnancy samples (rs = –0.08, P
value = 0.1) or for the second pregnancy samples (rs = –0.09,
P value = 0.5). Furthermore, there was no correlation between
the storage time and serum 25-OHD levels after controlling for
sampling age in either the first (rs = –0.02, P value = 0.7)
or in the second pregnancy samples (rs = –0.08, P value =
0.51). Age adjusted androstenedione levels had no significant
correlation with storage time (rs = 0.09).
We found a highly significant mean difference in the 25-
OHD levels of the paired sera withdrawn during winter (first
sample) vs. during summer (second sample; mean difference
µd = –18.4 nmol/l; P value ≤ 0.001; Table 2). This was true
(albeit to the opposite direction) also for individuals with the
first sampling season at summer and the second sampling sea-
son at winter (µd = 9.4 nmol/l; P value < 0.1; Table 2).
Comparing the average serum 25-OHD levels for groups of
individuals with different kinds of pairs of sampling seasons
(identical or opposite seasons), we found significant differences
when winter–winter samples were compared to all other types
of sample pairs (Table 3). The highest differences were observed
when comparing the average serum 25-OHD levels for winter–
winter samples with summer–summer (µd = 16.6 nmol/l, P
value≤ 0.001) and summer–winter samples (µd = 17.8 nmol/l;
P value ≤ 0.001). No significant differences were observed
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TABLE 2
Mean differences in serum 25-OHD (nmol/l) in paired sera of pregnant Finnish women by season of sample withdrawala
Mean Differences Between
Seasons of Sample Withdrawal Number (N ) 1st and 2nd Samples 95% Confidence Interval P Value
Winter–Summer 19 −18.4 −25.05 to −11.68 ≤ 0.001
Summer–Winter 15 9.4 −2.07 to 20.85 0.10
Summer–Summer 19 −1.9 −10.81 to 7.04 0.67
Winter–Winter 21 −5.1 −10.55 to 0.36 0.07
aAbbreviation is as follows: 25-OHD, 25-hydroxy vitamin D.
when similar comparisons were made for androstenedione levels
(Table 3).
DISCUSSION
Long-term storage of serum samples in biobanks at –25◦C
had no effect on 25-OHD and androstenedione concentrations.
Sampling season, however, had an effect. The average 25-OHD
concentrations were significantly lower in single and paired
samples taken during winter than in summer. If anything, an-
drostenedione concentrations tended to show the opposite.
The results from our study confirm previous studies on vi-
tamin D stability. Ocke et al. (7) analyzed serum vitamin D
concentrations of the same individual at intervals during 4 yr
and found approximately 10% difference (increase or decrease)
in mean vitamin D concentrations at given time points. They
concluded that the differences are most likely due to system-
atic differences in laboratory measurements. Bodnar et al. (8)
compared 25-OHD concentrations in sera stored for 40 yr with
those of sera stored for 2 yr in different individuals. Even though
the mean 25-OHD concentrations in the 40-yr-old samples were
lower than those of the 6-yr-old samples, the measurements were
similar in both. Seasonal and racial differences in mean 25-OHD
concentrations were found between both cohorts, implying that
if there was any deterioration in 25-OHD detectability, it was
similar across all the samples (8).
The first pregnancy samples of our cohort had been drawn
in paired years between 1984 and 2002 (6–24 yr ago). We did
not observe any correlation between serum 25-OHD concentra-
tions and the sampling time. However, we observed a consistent
statistically significant association between 25-OHD concentra-
tions and the sampling season. Also in the paired samples of the
same individuals, mean serum 25-OHD concentrations were
always higher in summer than in winter, an observation that
has been previously well documented in single sample analyses
(8,19,20).
The highest mean serum 25-OHD concentrations were found
in 1992, mainly due to very high summer levels of that year, an
observation that also holds true for the other years with mean
serum 25-OHD concentrations above 40 nmol/l. Likewise, the
TABLE 3
Differences in average serum androstenedione (ng/ml) and 25-OHD (nmol/l) of paired pregnancy samples of Finnish women
with specific pregnancy historya
Sampling Season Summer–Summer Summer–Winter Winter–Summer Winter–Winter
25-OHD, nmol/l (mean differenceb with p-value)
Summer–Summer 1.2(0.83) −6.9(0.11) 16.6(0.001)c
Summer–Winter −8.04(0.11) 17.8(0.001)c
Winter–Summer 9.7(0.02)c
Winter–Winter
Androstenedione ng/mL (mean differenceb with p-value)
Summer–Summer
Summer–Winter −0.3(0.4)
Winter–Summer −0.2(0.5) 0.1(0.8)
Winter–Winter −0.2(0.6) −0.6(0.1) −0.5(0.2)
aAbbreviation is as follows: 25-OHD, 25-hydroxy vitamin D.
bMean differences between averages of paired serum.
cMean 25-OHD concentrations for Winter–Winter paired samples are significantly lower than other season pairs.
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lowest total mean 25-OHD concentrations were found in 1996,
the year with the lowest summer 25-OHD concentrations. The
year 1996 was the only year with average summer 25-OHD con-
centrations less than 35 nmol/l. The low summer values in 1996
are probably due to the cold weather in 1996 (below the aver-
age for the century) and the fact that July 1996 was the wettest
July in 100 yr in parts of Finland (21). Thus, the possibility of
obtaining 25-OHD from sunlight was lower compared to other
years.
The diet of Finnish pregnant women has been fortified with
25-OHD since February 2003 (22). Our study samples were
predominantly taken before this date. Differences in serum 25-
OHD levels can therefore be attributed to seasonal variation.
This implies that summer 25-OHD status, which is a reflection
of exposure to UV light from the sun is the most important deter-
minant of 25-OHD status in our Nordic cohort. This is because
at latitudes above 35◦C (such as Finland), winter sunlight can-
not stimulate cutaneous production of pre-25-OHD since most,
if not all, of the UVB photons below 315 nm are absorbed by
the ozone layer (1). Our ability to detect the low summer serum
25-OHD values in the 1996 samples also reinforces the fact that
25-OHD is stable if stored properly at –25◦C for many years,
and possible deterioration is random.
For sample pairs with identical sampling seasons, average 25-
OHD levels for the second pregnancy samples were higher than
the first pregnancy levels for both winter–winter and summer–
summer pairs. These results are consistent with previous find-
ings that pregnancy increases nutrition awareness. Szwajcer et
al. (23) carried out interviews of 1-h duration with 60 women cat-
egorized in 5 groups: nulliparous, nonpregnant women; groups
of first, second, and third trimester pregnant nulliparous women;
and second pregnancy women in the first trimester. They found
that pregnancy leads to increased nutritional awareness, which
becomes a habit during the second pregnancy. The increased
health conscience among pregnant women may lead to frequent
sunlight exposure or increased dietary intake of foods rich in
vitamin D, which could translate into higher levels of average
25-OHD for women with second pregnancies compared to the
women with first pregnancies.
The androstenedione levels were somewhat higher in win-
ter than in summer. We found this also in the maternity cohort
samples used in Holl et al. study (24) (data not shown). These
results are consistent with experimental studies (25,26). Sing
and Krishna (25) determined seasonal changes in testosterone
and androstenedione levels in adult rats and observed the high-
est androstenedione levels in winter (November–January). In an
earlier study, Smith et al. (26) studied the effect of seasonal vari-
ability on the levels of androstenedione and testosterone in male
blue foxes. They observed a steady increase in the levels of both
hormones during winter months (November–March). Contrary
to our findings, Bjørnerem et al (11) and Brambilla et al. (27)
did not observe any seasonal variation in the serum androgens
(DHEA and testosterone) in blood samples of adult males and
females. DHEA is a precursor in synthesis of androstenedione,
which in turn is reversibly converted to testosterone (8). Thus,
seasonal stability in serum levels of androstenedione should
correlate with the levels of DHEA and testosterone.
In prospective epidemiologic studies using biomarkers as
quantitative estimates of past exposures and disease risk, se-
rial samples may provide a more reliable estimate compared
to static, single sample, estimates (28). Although there is com-
pelling evidence on the difference between summer and winter
levels of 25-OHD, to the best of our knowledge, no study has
compared serial (paired) samples taken both in similar and dif-
ferent seasons. Our study shows that significant differences in
25-OHD levels due to sampling season exist also for paired sam-
ples, especially if the samples are drawn in winter compared to
other seasons. We suggest that epidemiologic studies assessing
25-OHD levels and disease risk should appropriately stratify
and match subparts by sampling season and use serial samples
wherever possible to get better insight into the vitamin D status
of cases and controls.
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Introduction: Ecological and experimental studies suggest that vitamin D may be associated
with a reduced risk of ovarian cancer. In this study, we sought to determine the risk of
developing ovarian cancer according to serum 25-hydroxyvitamin D (25-OHD) concentra-
tions assessed on average 5 years before the diagnosis.
Methods: We conducted a population-based longitudinal case–control study nested within
the Finnish Maternity Cohort (FMC) which contains serum samples of virtually all pregnant
women in Finland since 1983. Among them, 201 ovarian cancers diagnosed within 10 years
of serum sampling were randomly selected as cases for this study. For each case, we
selected two controls matched for age, parity and sampling season (±4 weeks) and one con-
trol matched for age and parity but for the opposite sampling season (6 months ± 4 weeks).
Results: The relative risks (estimated as odds ratio, OR) for ovarian cancer comparing the
lowest quintile to the highest quintile of serum 25-OHD concentration were 1.8 (95% CI
0.9–3.5) among controls matched for the same season, and 1.1 (95% CI 0.6–2.2) among con-
trols matched for the opposite season. The OR among women with insufficient (<75 nmol/
L) serum 25-OHD concentration was 2.7 (95% CI 1.0–7.9, lower limit, 0.95) compared to that
among those with sufficient (P75 nmol/L) serum 25-OHD concentration. No differences in
the point estimates were observed between serous or mucinous histological subtypes of
ovarian cancer.
Conclusion: Overall, we did not observe a significant association between serum 25-OHD
concentrations and the risk of ovarian cancer. However, we found evidence suggestive of
an increased risk among women with low to insufficient serum 25-OHD concentrations.
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1. Introduction
Ovarian cancer is the most lethal gynaecological malignancy
and the fourth leading cause of cancer deaths among women
worldwide.1 About 191,000 new cases are diagnosed annu-
ally,2 with the highest incidence rates found in Caucasians
in northern and western Europe and in North America.2 De-
spite its considerable burden to cancer mortality in women,
very little is known about its aetiology.1
Ecological studies have suggested that theremay be an asso-
ciation between solar ultraviolet B radiation and risk of ovarian
cancer.3–6 It has been postulated that the protective effects of
sunlight on ovarian cancer are mediated via vitamin D, which
is a steroid-like hormone mainly produced through the action
of sunlight on the skin. Of the six ecological studies published
regarding ovarian cancer mortality rates and solar radiation,
four3–6 reported highermortality rates with lower regional sun-
lightwhereas twoobservednorelationship.7,8 Solar ultravioletB
(UVB) and high solar irradiancewere also shown to be inversely
associatedwith incidence ratesofovariancancer inaworldwide
study9 while there was no association in anothermultinational
study.10Likewise, epidemiologicalstudiesexamining theassoci-
ation of dietary vitamin D and ovarian cancer have been
equivocal.11–14 However, one recent study that evaluated the
association of plasma vitamin D and ovarian cancer risk
reported a beneficial effect among certain subgroups.15
Vitamin D, by inducing cellular differentiation and apopto-
sis, inhibiting cellular proliferation, invasiveness and angio-
genesis possesses anti-carcinogenic properties.16 Vitamin D
exerts its action through the vitamin D receptor (VDR) and
VDRs are present in both normal ovarian tissues and ovarian
cancer cells.17–19
In this nested case–control study, we examined the rela-
tionship between serum vitamin D concentration and risk
of ovarian cancer exploiting the resources of the nationwide
Finnish Maternity Cohort (FMC), established in 1983.20
2. Materials and methods
2.1. Finnish Maternity Cohort
We carried out a case–control study nested within the Finnish
Maternity Cohort (FMC). The FMC was established by the Na-
tional Institute for Health and Welfare, Finland in 1983.20 Fol-
lowing an informed consent, first trimester blood samples are
withdrawn from pregnant women at the municipal maternity
care units to screen for intrauterine infections. After the
screening has been done, the remaining sample (1–3 mL of
serum) is stored at )25 C in polypropylene cryo vials in a
well-protected biorepository at the National Institute for
Health and Welfare in Oulu. More than 98% of pregnant wo-
men in Finland have donated blood samples to the cohort
since 1983 and currently over 1.3 million samples are kept
in storage. Each year about 60,000 new serum samples are
added to the repository.
2.2. Identification of cases and controls
Incident ovarian cancer cases were identified by the popula-
tion-based Finnish Cancer Registry (FCR). All cancer cases
diagnosed in Finland since 1953 are reported to the FCR
(reporting mandatory since 1961). The coverage of the FCR is
virtually complete with no losses to follow-up.21 Every resi-
dent of Finland has a unique personal identity code that is
also used in official health registries such as the FMC and
FCR. Our study cohort was record linked with the cancer reg-
istry data by using the personal identity code.
Two-hundred and one random ovarian cancer cases diag-
nosed within 10 years of serum sampling were selected for
this study. If a case had donatedmore than one samplewithin
this 10-year period, the sample donated closest to cancer
diagnosis was selected. Time between serum donation and
cancer diagnosis ranged between 2 years and 10 years with
a median of 5 years. Among the 201 cancer cases, 195 had his-
tological confirmation. Of the 195 with histological confirma-
tion, 76 (39%) were serous, 70 (35.9%) mucinous, 15 (7.7%) sex
cord stromal tumours, 11 (5.6%) endometrioid, 9 (4.6%) germ
cell tumours, 5 (2.6%) clear cell tumours and 9 (4.6%) others.
The tumours were left-sided in 74 (45.4%) cases, right-sided
in 66 (40.5%) cases and bilateral in 23 (14.1%) cases.
The cases were matched with two sets of controls. The
first set of controls consisted of women from the FMC who
were alive and free of cancer at the time of diagnosis of the
case and were matched for (i) age at sample withdrawal ±1
year, (ii) parity and (iii) date of index blood sampling ±4 weeks
(same season as case). For each case, 2 controls were selected
and 400 serum sampleswere available for the laboratory anal-
ysis. The second set of controls consisted of women from the
cohort, who were alive and free of cancer at the time of diag-
nosis of the cases and whose serum samples were taken at
the opposite seasons to the cases (approximately six
months ± 4 weeks apart). These controls were matched for
(i) age at sample withdrawal ±1 year and (ii) parity. One con-
trol per case was selected. In all, 201 cases, 398 same season
controls and 199 opposite season controls were available.
All study samples were previously unthawed. The study
was approved by the ethical committee of the National Insti-
tute for Health and Welfare, Finland.
2.3. Laboratory analysis
Quantification of 25-hydroxyvitamin D (25-OHD) was done at
the Department of Medical Biosciences, University of Umea˚,
Umea˚, Sweden using a 25-OHD radioimmunoassay (RIA) from
IDS Ltd., Boldon, UK. The manufacturer stated a specificity (%
cross-reactivity) of 100% for 25-OHD3, 75% for 25-OHD2, 100%
for 24, 25-OH2D3, and less than 0.01% and 0.3% for cholecal-
ciferol (D3) and ergocalciferol (D2), respectively. The within,
between and total coefficients of variations (CVs) of the assay
were 7.8%, 9.6% and 12.4% at level 28.4 nmol/L 25-OHD, and
4.1%, 7.4% and 8.5% at 107 nmol/L 25-OHD, respectively. Case
and control samples belonging to each other study set were
assayed together, ordered randomly and labelled to mask
case–control status.
2.4. Statistical analysis
Two of the samples had 25-OHD concentrations of less than
2 nmol/L, which were considered to be outliers and set to
missing. Descriptive data of cases and controls with regard
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to age at sample withdrawal and cancer diagnosis, age at last
full term pregnancy, number of pregnancies, gestational days
and bench lag-time were recorded.
Quintile cut-off points were determined using 25-OHD
concentrations of the controls. Quintiles of 25-OHD concen-
trations were used to estimate the relative risk of ovarian can-
cer and their 95% confidence intervals (CIs) by conditional
logistic regression and are expressed as odds ratio (OR). The
multivariate model was adjusted for age at last full term preg-
nancy and bench lag-time (days between sample withdrawal
and freezing it for storage). Separate analyses were conducted
for the main different histological subgroups of ovarian can-
cer available vis-a-vis, serous and mucinous tumours using
cases and controls that were matched for the same season.
Risk of ovarian cancer was also compared among women
with serum 25-OHD levels above 75 nmol/L and those with
serum 25-OHD levels below 75 nmol/L.22,23 All statistical anal-
yses were performed using SPSS 15 for windows (SPSS Inc.,
Chicago, IL). Two-sided p < 0.05 was considered statistically
significant.
3. Results
The age range for cases and controls was from 17.5 to 44
years. The median ages at the time of serum sampling were
31.5 and 31.4 years for cases and controls, respectively. The
median duration between serum sampling and cancer diag-
nosis was 5 years. The median number of pregnancies was
2 with a range of 1–8 for cases and 1–10 for controls. Median
serum 25-OHD concentrations were 35.0, 35.8 and
34.3 nmol/L among cases, same season controls and opposite
season controls, respectively (Table 1).
We first compared the relative risk of ovarian cancer by
quintile groups of serum 25-OHD among cases and controls
whose serum samples were taken within the same season
and had been matched for age and parity. Low levels of 25-
OHD appeared to be associated with increased risk of ovarian
cancer. The strongest association did, however, not reach sta-
tistical significance (1st quintile versus 5th quintile: OR, 1.8, CI
0.9–3.6; ptrend = 0.26) age at last full term pregnancy and bench
lag-time adjusted (Table 2). Women with insufficient serum
vitamin D concentrations had a threefold increased risk of
ovarian cancer compared to women with sufficient serum
concentrations (OR 2.8, 95% CI 1.0–7.9, lower limit 0.95, p-va-
lue = 0.06) (Table 3). Different point estimates were obtained
when control samples from opposite seasons were used.
The point estimates were closer to unit risk (1st quintile ver-
sus 5th quintile: OR, 1.1, CI O.6–2.2; ptrend = 0.49) (Table 2).
No significant associations were observed between quin-
tiles of 25-OHD concentrations and ovarian cancer risk when
the analyses were carried out for the two main histological
groups. Comparing the 1st to the 5th quintiles, the ORs were
1.3 (95% CI 0.7–3.2) for serous tumours, and 1.2 (95% CI 0.4–3.1)
for mucinous tumours. Stratification for seasonality did not
show any further differences (data not shown).
4. Discussion
In this longitudinal population-based nested case–control
study, we observed no significant relationship between serum
25-hydroxyvitamin D concentrations and the risk of ovarian
cancer. However, there appeared to be a tendency to in-
creased risk among those who had low or insufficient serum
25-hydroxyvitamin D concentrations compared to those who
had sufficient concentrations.
Perhaps, one of the reasons why an association between
25-OHD and ovarian cancer was not apparent using the quin-
tile distribution of 25-OHD was the generally relatively low
serum 25-OHD concentrations in the cohort. Recently, due
to a greater understanding of the interplay between vitamin
D and its regulatory hormones, there have been discussions
on what constitutes vitamin D deficiency.22–24 A 25-OHD con-
centration of less than 50 nmol/L is considered to represent
vitamin D deficiency, and that between 50 and 72 nmol/L is
considered to represent relative insufficiency while concen-
trations above 75 nmol/L are thought to indicate vitamin D
sufficiency.22 Using these cut-off values, we found evidence
suggestive of an increased risk of ovarian cancer among wo-
men with insufficient serum vitamin D concentrations com-
pared with women with sufficient vitamin D concentrations.
This supports results from the experimental studies which
suggest that high vitamin D concentrations may be needed
to prevent against ovarian cancer.25,26
The results from our study are similar to those of another
recent prospective study by Tworoger and colleagues.15 The
authors did not observe any association between plasma 25-
Table 1 – Baseline characteristics of the study population who donated serum samples to the Finnish Maternity Cohort
between 1983 and 2006.
Cases (n = 201) Controla (n = 398) Controlb (n = 199)
Median (range) Median (range) Median (range)
Age at serum sampling 31.5 (17.5–43.2) 31.5 (17.8–43.9) 31.4 (18.9–43.6)
Age at last full term pregnancy 32.7 (17.5–50.1) 33.6 (17.8–50.9) 33.2 (18.9–51.2)
Number of pregnancies 2 (1–8) 2 (1–10) 2 (1–10)
Lag-time to cancer diagnosis, years 5 (0.5–9.8)
Duration of gestation, days 74.0 (40–89) 76.5 (33–91) 81.0 (35–87)
Bench lag-time, days 2.0 (0–12) 3.0 (0–9) 3.0 (0–9)
25-OHD concentration (10th and 90th percentiles), nmol/L 35.0 (20.3, 56.4) 35.8 (22.9, 61.3) 34.3 (21.5, 65.4)
a Same season controls. Serum samples were taken within 1 month to those of cases.
b Opposite season controls. Serum samples were taken during the opposite season to those of cases, i.e. approximately 6 months ± 4 weeks
apart.
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hydroxyvitamin D and ovarian cancer risks in their overall
analysis but women with adequate versus inadequate 25-
hydroxyvitamin D levels had a decreased risk of borderline
significance (RR, 0.7; 95% CI, 0.4–1.1). In addition, Tworoger
and colleagues reported a stronger effect among overweight
women. Unfortunately, data on body weight were not avail-
able for the women in our sub-sample of the FMC to explore
this hypothesis.
The ovary together with other tissues such as the kidney,
breast, colon and prostate express the enzyme, 1 alpha-
hydroxylase, (1aOHase).25 This enzyme converts 25-OHD to
1, 25-(OH)2D, thus, the biologically active form of vitamin D
is available locally in the ovaries and other tissues that ex-
press the enzyme. Since the ovaries also express VDR18,19
and the effects of vitamin D are exerted through the VDR, it
is biologically plausible that vitamin D may have effects on
the ovaries.
Ovarian cancer is a heterogeneous disease. The histologi-
cal subtypes have different risk factors (both genetic and
environmental) and dissimilar epidemiological and clinical
characteristics.27 In our study, we did not observe any differ-
ences in risk related to vitamin D concentration by histology.
Apart from serous and mucinous cancers, the other histolog-
ical subgroups, however, had very few cases.
The following limitations of our study need to be taken
into account: (i) oral contraceptive use increases serum 25-
OHD concentrations28,29; and use of oral contraceptives also
protects against ovarian cancer.30 Hence, use of oral contra-
ceptives is a confounder in the association between 25-OHD
and ovarian cancer. While this was controlled for by sample
withdrawal during 12th to 14th week of pregnancy (when
use of oral contraceptive must have been stopped for some-
time), we did not have information on the use of oral contra-
ceptives among our study subjects. (ii) Our study subjects
were limited to fertile women in their reproductive ages
who were matched for parity. Therefore we do not know if
similar results will be obtained in infertile and/or post-meno-
pausal women since they were not represented in our study.
Serum 25-OHD concentration is a reflection of endogenous
synthesis taking place in the skin under the influence of UVB
irradiation and exogenous production from dietary in-
take.22,31 Vitamin D first undergoes hydroxylation in the liver
to 25-hydroxyvitamin D (25-OHD) before undergoing further
hydroxylation to 1, 25-dihydroxyvitamin D (1, 25-(OH)2D) in
the kidneys.22 While 1, 25-(OH)2D is the most biologically ac-
tive form of vitamin D, 25-OHD is considered as the best
gauge of individual vitamin D status,22,31,32 making measure-
ment of serum/plasma 25-OHD concentrations the ideal way
to determine vitamin D status.
Strengths of our study include (i) its population-based nat-
ure; the FMC covers 98% of pregnant Finnish women.20 (ii) Its
prospective nature; the blood samples were collected before
cancer diagnosis. Furthermore, the study samples were also
collected before the start of vitamin D supplementation
among pregnant women in Finland. In addition, we were able
to explore the possible effects of matching for season of blood
collection on the results. The reason why we selected the
opposite season control group was to determine how much
variation in risk estimates can occur when such controls are
used as compared to when same season controls are used.
Table 2 – Relative risks (odds ratio, OR, with 95% confidence interval, CI) of ovarian cancer by quintile of serum vitamin D
concentration in fertile aged Finnish women followed up for up to 10 years after serum withdrawal.
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 Ptrend
Among cases and controls who donated serum in same season (±4 weeks)a
Quintile values, nmol/L <26.4 26.4–32.9 32.9–39.9 39.9–53.1 P53.1 0.26
n, cases, control 46/79 41/81 41/81 44/78 28/79
OR, crude 1.6 (0.9–2.9) 1.4 (0.8–2.6) 1.4 (0.8–2.5) 1.6 (0.9–2.7) 1.0 (reference)
OR, adjustedb 1.8 (0.9–3.5) 1.6 (0.8–3.1) 1.5 (0.8–2.8) 1.6 (0.9–2.9) 1.0 (reference)
Among cases and controls who donated serum in opposite seasons (6 months ± 4 weeks)a
Quintile values, nmol/L <25.3 25.3–32.2 32.2–38.8 38.8–51.9 P51.9 0.49
n, cases, control 42/39 36/41 41/39 41/39 41/40
OR, crude 1.1 (0.6–2.0) 1.3 (0.7–2.3) 1.1 (0.6–2.0) 1.1 (0.6–2.0) 1.0 (reference)
OR, adjustedb 1.1 (0.6–2.2) 1.3 (0.6–2.5) 1.2 (0.6–2.3) 1.2 (0.6–2.3) 1.0 (reference)
a Cases and controls were also matched for parity and age.
b Adjusted for age at last full term pregnancy and bench lag-time.
Table 3 – Relative risks (odds ratio, OR, with 95% confidence interval, CI) of ovarian cancer in women with sufficient serum
vitamin D concentrations compared with those of fertile aged Finnish women with insufficient serum vitamin D
concentrations followed up for up to 10 after serum withdrawal.a
Cases Controls OR OR, adjusted (95% CI) P-value
SufficientP 75 nmol/L (reference)b 4 21 1.0 0.06
Insufficient (<75 nmol/L) 196 377 2.8 2.7 (1.0c–7.9)
a Analysis carried out among cases and controls matched for age, parity and season of serum donation (±4 weeks).
b Refs. 22,23.
c Lower limit, 0.95.
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We believe that this may have important repercussions on
studies examining vitamin D/disease associations especially
in serial sample studies. In this study, deliberate opposite sea-
son controls showed lower, close to unit risk estimates when
compared to season-matched controls. This could mean that
if an effect exists, not taking into account the input of season-
ality probably confounds the estimation. In epidemiological
studies ascertaining vitamin D disease associations, adequate
matching of cases and controls for time of sample collection
and/or statistical control is essential.
In conclusion, although we did not observe statistically
significant association between serum 25-OHD concentra-
tions and risk of ovarian cancer, low serum 25-OHD concen-
trations may be associated with an increased risk of
developing the disease. As few modifiable factors are known
to reduce ovarian cancer risk, further prospective data on
vitamin D and ovarian cancer are of interest.
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Introduction: Ovarian cancer has very few known modifiable risk factors but dietary
studies suggest a role for vitamin D and calcium in the prevention of ovarian cancer.
Thus, we investigated the association between pre-diagnostic serum calcium and 25-
hydroxyvitamin D (25-OHD) on the risk of later development of ovarian cancer.
Methods: We conducted a population-based nested case–control study within the
Finnish Maternity Cohort (FMC). The cohort subset comprised 172 ovarian cancer cases
with 172 matched controls (age ± 1 year, parity and season of blood donation ±
2 weeks).
Results: We observed a significant inverse association between calcium and ovarian can-
cer risk. Relative risk (estimated as odds ratio, OR) comparing the highest quartile to the
lowest quartile was significantly decreased; 0.41 [95% confidence interval (CI) 0.19–0.85, P-
trend 0.004]. Even though a comparable association between 25-OHD and ovarian cancer
did not reach statistical significance (OR 0.57, 95% CI 0.26–1.24, P-trend 0.07), having suf-
ficient (>75 nmol/L) serum 25-OHD levels compared to insufficient serum 25-OHD was
associated with a significantly decreased risk of ovarian cancer (OR 0.32; 95% CI 0.12–
0.91, p-value 0.03). No synergistic protective interaction between high levels of calcium
and 25-OHD against ovarian cancer was observed, the joint effect being just multiplica-
tive.
Conclusion: Calcium and vitamin D act independently to reduce the risk of ovarian cancer.
The decreased risk of ovarian cancer associated with pre-diagnostic serum calcium and
vitamin D needs to be evaluated further for possible new insights into ovarian cancer
prevention.
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1. Introduction
Ecological, dietary and experimental studies suggest that
vitamin D may be associated with reduced risk of ovarian
cancer.1–4 So far, only three epidemiological studies have di-
rectly explored this association by relating serum 25-hydrox-
yvitamin D (25-OHD) to risk, but the results were not
conclusive.5–7 Nevertheless, in two of the three studies, wo-
men with sufficient vitamin D concentrations tended to have
lower risk of ovarian cancer overall.5,6 Thus, more studies to
characterise a possible association of ovarian cancer with
vitamin D and explore the effect of additional factors that
may modify risk are of interest.
The classical function of vitamin D is to facilitate the
intestinal absorption of calcium but evidence is mounting to
suggest that the actions of vitamin D and calcium on physio-
logic processes may be synergistic.8,9 High extracellular cal-
cium can modulate vitamin D metabolism in favour of
increased conversion to 1,25-dihydroxyvitamin D (the active
form of vitamin D) which in turn may up-regulate the expres-
sion of the calcium receptor and increase intestinal calcium
absorption.9 In support, a randomised clinical trial recently
demonstrated that while calcium supplementation reduced
the risk of all-cause cancer among women, the protective ef-
fect wasmore pronounced amongwomenwith combined cal-
cium and vitamin D supplementation.10 Along the same lines,
the protective effect of high dietary calcium intake on colo-
rectal cancer incidence was strongest in subjects with highest
vitamin D intake in a large pooled analysis of 10 cohort
studies.11
The independent role of serum calcium in ovarian cancer
has not been explored so far. While some studies have ob-
served an inverse association of ovarian cancer with dietary
intake of calcium, others have observed positive or no associ-
ations.12–17 Nevertheless, the relationship between serum cal-
cium concentrations and dietary calcium intake is complex.
Serum calcium concentrations are tightly regulated and there
is very little correlation between it and dietary calcium in-
take.18 To the best of our knowledge, no previous study has
investigated the effect of serum calcium and the joint effects
of serum calcium and vitamin D levels on ovarian cancer risk.
The aim of this study was to evaluate possible independent
and joint effects of vitamin D and calcium on the risk of ovar-
ian cancer.
2. Material and methods
2.1. Finnish Maternity Cohort
This study is a prospective, population based case–control
study nested within the Finnish Maternity Cohort (FMC).
The FMC was established by the National Institute for Health
and Welfare (formerly National Public Health Institute), Fin-
land, in 1983.19 Following an informed consent, first trimester
blood samples are withdrawn from pregnant women at the
municipal maternity care units to screen for intrauterine
infections. After the screening has been done, the remaining
sample (1–3 mL of serum) is stored in polypropylene cryo vials
at )25 C in a well-protected biorepository at the National
Institute for Health and Welfare, Oulu. More than 98% of
pregnant women in Finland have donated blood samples to
the cohort since 1983 and currently about 1.6 million samples
are kept in storage. Each year about 60,000 new serum sam-
ples are added to the repository.
2.2. Identification of cases and controls
Incident ovarian cancer cases were identified by the popula-
tion-based Finnish Cancer Registry (FCR). All cancer cases
diagnosed in Finland since 1953 are reported to the FCR
(reporting mandatory since 1961). The coverage of the FCR is
virtually complete with no losses to follow-up.20 Every resi-
dent of Finland has a unique personal identity code that is
also used in official health registries like the FMC and the
FCR. These codes were used as the linkage key. Ovarian can-
cer cases who had donated serum samples to the FMC more
than once, at least 1 year apart, before cancer diagnosis were
selected for this study. Of the 215 cases that fulfilled these cri-
teria, those who donated their last sample within 1 year be-
fore the cancer diagnosis and those who had been selected
for a previous study of ovarian cancer and vitamin D within
this cohort5 were excluded, leaving 172 cases. There were
166 cases with histological confirmation of which 68 (41%),
60 (36%) and 15 (9%) were serous, mucinous and endometroid
cancers, respectively.
Eligible controls were women from the FMC who were
alive and free of cancer at the time of diagnosis of the index
case and who also had donated at least two serum samples
during different pregnancies to the FMC. The controls were
matched for (i) age at sample withdrawal ± 1 year, (ii) parity
and (iii) date of index blood sampling ±2 weeks for both sets
of samples. One control with paired samples was selected
for every case. For this study, the first set of serum samples
for cases and controls was used.
The study was approved by the ethical committee of the
National Institute for Health and Welfare, Finland.
2.3. Laboratory analysis
Quantification of 25-OHD was performed at the Department
of Medical Biosciences, University of Umea˚, Umea˚, Sweden,
using a 25-OHD radioimmunoassay (RIA) from IDS Ltd., Bol-
don, United Kingdom. The manufacturer stated a specificity
(% cross-reactivity) of 100% for 25-OHD3, 75% for 25-OHD2,
100% for 24, 25-OH2D3 and less than 0.01% or 0.3% for chole-
calciferol (D3) and ergocalciferol (D2), respectively. The with-
in, between and total coefficients of variation (CV) of the
assay were 4.3%, 17.1% and 17.7% at level 32.9 nmol/L, respec-
tively. Serum 25-OHD concentrations were defined as follows:
(i) sufficient > 75 nmol/L, (ii) relative insufficient 50–75 nmol/L
and (iii) insufficient or deficient <50 nmol/L.21 Outliers were
defined as concentrations exceeding three times the inter-
quartile range and were set to missing (n = 1 for 25-OHD).
Quantification of serum calcium was performed at the
Clinical Chemistry Laboratory, O¨stersunds Hospital, O¨sters-
und, Sweden, using the Roche/Hitachi cobas c system ana-
lyzer (Roche Diagnostics GmbH, D68298 Mannheim,
Germany). The total coefficient of variation (CV) of the assay
was 2.4% at level 2.0 mmol/L. Case and control samples
belonging to the same study set were assayed together, but
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ordered randomly and labelled to mask case–control status.
Three samples had insufficient volume to perform the labora-
tory assays.
2.4. Statistical analysis
Descriptive statistics are presented as mean (standard devia-
tion) for all other data andmedian and percentiles for calcium
and 25-OHD.
Quartile cut-off points for both 25-OHD and calcium were
determined using the distribution among the controls. Condi-
tional logistic regression was used to calculate odds ratio with
95% confidence interval (OR with 95% CI) for ovarian cancer in
the different quartiles of 25-OHD and calciumusing the lowest
quartiles as the reference category. Tests for trendwere calcu-
lated using continuous scale of the variables, log-transformed
for 25-OHD because the overall distribution was slightly
skewed even though the season-specific distributions were
normal. The effect of adjustment for age at first full-termpreg-
nancy, age at last full-termpregnancy, gestational day at blood
donation and region of residence (North, South,West, East and
Central Finland)were investigated inmultivariatemodels, and
variables that altered risk estimates by more than 5% were re-
tained in the final models (age at first full-term pregnancy
and region of residence). Mutual adjustments of vitamin D
models for calcium concentrations and vice versa were also
performed but the results are very identical to those obtained
without the mutual adjustments and are thus not presented.
Secondaryanalyseswerecarriedout excludingcases (and their
matched controls) whose cancers were diagnosed within 1–
3 years of serum sampling (analysis was also done excluding
cases diagnosed within 1–2 years of sampling but the results
were identical to those obtained excluding cases diagnosed
within 1–3 years and thus not presented) and for women with
sufficient/insufficient serum vitamin D (>75 nmol/L).21
To determine the possible synergistic effects of 25-OHD
and calcium, we categorised the subjects into four groups
based on each individual’s combined 25-OHD and calcium
status. (i) Low 25-OHD /low calcium – women with both 25-
OHD and calcium categories within the 1st 3 quartiles, i.e.
(25-OHD Q1, Q2, Q3 + calcium Q1, Q2, Q3). This represented
the reference category, (ii) high 25-OHD/low calcium – women
whose 25-OHD were within the 4th quartile but whose cal-
cium were within the 1st 3 quartiles (25-OHD Q4 + calcium
Q1, Q2, Q3), (iii) low 25-OHD/high calcium – women with 25-
OHD within the 1st 3 quartiles but calcium within the 4th
quartile (25-OHD Q1, Q2, Q3 + calcium Q4) and (iv) high 25-
OHD/high calcium – both 25-OHD and calcium were within
the 4th quartiles (25-OHD Q4 + calcium Q4). Testing for effect
modification was done with a likelihood ratio test to compare
two nestedmodels, by considering the difference between the
model-specific scaled deviances. All statistical analyses were
performed using SPSS 18 for windows (SPSS, Inc., Chicago IL).
Two sided p < 0.05 was considered statistically significant.
3. Results
Mean age at serum sampling for both cases and controls was
the same (29.9 years). Likewise ages at first full-term and last
full-term pregnancies and number of pregnancies were al-
most identical for both cases and controls. The mean lag time
between serum sampling and cancer diagnosis was 6.4 years
(range 1–13.5 years). Median 25-OHD concentrations were
39.2 nmol/L (90th percentile 65.4) and 40.0 nmol/L (90th
percentile 73.4); while median calcium concentrations were
2.3 mmol/L and 2.4 mmol/L for cases and controls, respec-
tively (Table 1). There was no correlation between serum
25-OHD and calcium concentrations among cases (rs =
)0.02, p-value 0.82) and controls (rs = 0.07, p-value 0.39).
Mean serum 25-OHD concentrations for both cases and
controls were highest in summer and autumn and lowest in
winter. Though the season-matched mean serum 25-OHD
levels were higher among controls compared to cases for all
the seasons, the differences in means were not statistically
significant. The highest differences in means were observed
for spring (8.5 nmol/L) and were the lowest for summer
(3.9 nmol/L) (Fig. 1).
Odds ratio comparing the fourth quartile of serum 25-
OHD concentration to the first quartile was 0.63 (95% confi-
dence interval (CI) 0.29–1.34, P-trend 0.10). Adjusting for
age at first full-term pregnancy and region of residence,
the odds ratio was OR 0.57 (95% CI 0.26–1.24, P-trend 0.07).
When cases whose cancers were diagnosed within 1–3 years
of serum sampling were excluded from the analysis, the
odds ratio was slightly reduced and the trend test reached
statistical significance, OR 0.43 (95% CI 0.18–1.05, P-trend
0.02) (Table 2). Women with sufficient 25-OHD concentra-
tions (>75 nmol/L) had a significantly reduced risk of ovarian
cancer compared to those with insufficient serum concen-
trations (OR 0.32; 95% CI 0.12–0.91, p-value 0.03). The number
of women with sufficient serum 25-OHD concentrations
were, however, small (20 women, 5 cases and 15 controls).
The results were identical when season-defined quartiles
were used.
Increasing serum calcium concentration was also inver-
sely associated with ovarian cancer risk. Comparing the
highest to the lowest quartile, the odds ratios were 0.46
(95% CI 0.23–0.95, P-trend 0.005) and 0.41 (95% CI 0.19–
0.85, P-trend 0.004) in the first and multivariate adjusted
models, respectively. Exclusion of cases diagnosed within
1–3 years of serum sampling had no material effect on
the point estimate; OR 0.37 (95% CI 0.16-0.85, P-trend
0.002) (Table 3).
Compared to women who had low calcium/low 25-OHD
concentrations, those who had high calcium/high 25-OHD
levels had an odds ratio of 0.26 (95% CI 0.07–0.90). Likewise,
the odds ratios among women with high calcium/low 25-
OHD and low calcium/high 25-OHD were OR 0.41 (95% CI
0.19–0.87) and 0.51 (95% CI 0.29–1.05), respectively (see Ta-
ble 4). Calcium does not modify the effect of 25-OHD
(p = 0.25) and 25-OHD does not modify the effect of calcium
(p = 0.12). The interaction is multiplicative.
4. Discussion
To the best of our knowledge, this is the first prospective
study to examine the association of both serum calcium
and 25-OHD with the risk of ovarian cancer. Our findings (i)
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Fig. 1 – Mean serum vitamin D concentration (±2 SE) by season of blood donation among cases and controls.
Table 2 – Relative risk (estimated as odds ratio, OR, with 95% confidence intervals, CI) of ovarian cancer by quartile of serum
25-hydroxyvitamin D concentrations among Finnish women followed up to 13 years after sample donation.
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend Q4 versus Q1–3
Quartile values, nmol/L <31.5 31.5–40.0 40.1–57.7 P57.8
n, cases/controla 42/43 44/44 52/42 30/43
OR 1.0 (reference) 1.05 (0.58–1.92) 1.25 (0.67–2.32) 0.63 (0.29–1.34) 0.10 0.56 (0.30–1.04)
OR, adjustedb 1.0 (reference) 1.01 (0.54–1.87) 1.13 (0.60–2.12) 0.57 (0.26–1.24) 0.07 0.54 (0.28–1.02)
Excluding cases who donated serum samples within 1–3 years of cancer diagnosis
Quartile values <32.0 32.1–40.5 40.6-58.1 P58.2
n, cases/control 36/33 37/33 35/35 25/36
OR, adjustedb 1.0 (reference) 0.93 (0.48–1.82) 0.79 (0.39–1.63) 0.43 (0.18–1.05) 0.02 0.49 (0.24–1.01)
a Controls were matched for age at serum sampling, parity and date of blood donation (±2 weeks).
b Adjusted for age at first full-term pregnancy and region of residence.
Table 1 – Baseline characteristics of ovarian cancer cases and matched, incidence density sampled controls who donated
serum samples to the Finnish Maternity Cohort between 1983 and 2007.
Cases
(n = 172)
Controls
(n = 172)
Age at serum sampling, years 29.9 (4.3) 29.9 (4.3)
Age at first full-term pregnancy, years 26.9 (4.3) 27.4 (4.3)
Age at last full-term pregnancy, years 31.4 (4.1) 32.1 (4.6)
Age at cancer diagnosis, years 36.4 (5.1)
Lag time to cancer diagnosis, years (minimum, maximum) 6.4 (1, 13.5)
Number of pregnancies 2.5 (1.0) 2.5 (1.0)
Gestational day at blood donation, d 76.6 (21.3) 78.9 (27.7)
25-OHD concentration nmol/L, median (10th, 90th percentile) 39.2 (23.8, 65.4) 40.0 (24.6, 73.4)
Calcium concentration mmol/L, median (10th, 90th percentile) 2.3 (1.9, 2.6) 2.4 (2.1, 2.8)
All values are expressed as mean (standard deviation) unless otherwise stated.
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a strong inverse association between serum calcium concen-
tration and ovarian cancer risk with and without high serum
25-OHD concentrations, (ii) a borderline inverse association
between high serum 25-OHD concentrations and ovarian can-
cer risk, but (iii) no synergistic interaction between 25-OHD
and calcium with regard to ovarian cancer risk.
4.1. Calcium and ovarian cancer
An inverse relationship between dietary calcium and ovarian
cancer has been reported in some studies but not all.12–17
However, serum calcium does not reflect dietary calcium in-
take as this relationship is influenced by vitamin D, parathy-
roid hormone (PTH) and other dietary factors.18,22 The
Norwegian study18 observed no significant effect of dietary in-
take of calcium and vitamin D on serum calcium concentra-
tions in women. Though the biological processes by which
calcium may influence ovarian cancer are largely unknown,
possible mechanisms include (i) the effects of calcium on
apoptosis, cell growth and proliferation,23,24 (ii) effects of the
calcium receptor (CaR) on cell proliferation and differentia-
tion24,25 and (iii) effects of calcium on down-regulating PTH
production.26
Calcium regulates many important steps in the apoptotic
pathway from early signalling to chromatin cleavage but the
precise molecular mechanisms involved are not clear.23 The
calcium receptor also regulates homeostasis in response to
changes in extracellular calcium concentrations. It modulates
the equilibrium between proliferation and differentiation in
response to changes in extracellular calcium concentra-
tions.24,25 Loss of CaR-induced response to extracellular cal-
cium has been observed in ovarian cancers.25
In hypocalcaemia, PTH stimulates the conversion of
25-hydroxyvitamin D to 1,25-dihydroxyvitamin D in the kid-
neys. This leads to an increase in vitamin D availability which
subsequently leads to increased calcium absorption and ser-
um calcium.26 The increase in serum calcium then provides
a negative feedback causing a suppression of PTH production
and reducing serum PTH levels. It has been hypothesised that
PTH may be a tumour promoter acting as a co-mitogen and
anti-apoptotic factor.26 It also increases hepatic and osteo-
blastic synthesis of insulin-like growth factor-1 (IGF-1)26,27
which has strong mitogenic effects and has been implicated
in the pathogenesis of ovarian and other cancers.28,29 The
presence of growth regulating PTH receptors and PTH-related
protein (PTH-rP) has been noted in cancer cells, including
ovarian cancer.30 However, to what extent the PTH-induced
increases in IGF-1 concentrations alter the physiological bal-
ance of IGF-1 is unknown. Hence, by down-regulating PTH
production, calcium potentially mitigates against the mito-
genic and anti-apoptotic effects of PTH. This same hypothesis
has also been proposed as one of the likely means by which
vitamin D may protect against cancer,26 but in our study,
the protective effect of high calcium concentrations was seen
irrespective of the vitamin D status.
4.2. Vitamin D and ovarian cancer
No previous study has observed a significant overall associa-
tion between serum vitamin D and risk of ovarian cancer
but borderline inverse associations have been reported in
subgroup analyses.5,6 We also observed a borderline inverse
relationship between serum vitamin D and ovarian cancer
in a secondary analysis excluding caseswho donated samples
Table 3 – Relative risk (estimated as odds ratio, OR, with 95% confidence intervals, CI) of ovarian cancer by quartile of serum
calcium concentrations among Finnish women followed up to 13 years after sample donation.
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend
Quartile values, mmol/L <2.2 2.2–2.4 2.4–2.6 P2.6
n, cases/controla 46/39 50/45 48/44 26/44
OR 1.0 (reference) 0.99 (0.54–1.85) 0.86 (0.46–1.60) 0.46 (0.23–0.95) 0.005
OR, adjustedb 1.0 (reference) 1.04 (0.55–1.96) 0.84 (0.44–1.61) 0.41 (0.19–0.85) 0.004
Excluding cases who donated serum samples within 3 years of cancer diagnosis
Quartile values <2.2 2.2–2.4 2.4–2.6
n, cases/control 35/31 43/35 37/32 20/39
OR, adjustedb 1.0 (reference) 1.26 (0.59–2.67) 0.97 (0.46–2.08) 0.37 (0.16–0.85) 0.002
a Controls were matched for age at serum sampling, parity and date of blood donation (±2 weeks).
b Adjusted for age at first full-term pregnancy and region of residence.
Table 4 – Joint effect of exposure of 25-hydroxyvitamin D and calcium on the relative risk (estimated as odds ratio, OR, with
95% confidence intervals, CI) of ovarian cancer among Finnish women.
Group 1 Group 2 Group 3 Group 4
Case/control 116/96 26/32 21/33 5/11
OR, adjusteda 1.0 (reference) 0.51 (0.29–1.05) 0.41(0.19–0.87) 0.26 (0.07–0.90)
Low vitamin D/low calcium – Vit D (Q1, Q2, Q3) and calcium (Q1, Q2, Q3). High vitamin D/low calcium – Vit D (Q4) and calcium (Q1, Q2, Q3). Low
vitamin D/high calcium – Vit D (Q1, Q2, Q3) and calcium (Q4). High vitamin D/high calcium– Vit D (Q4) + calcium (Q4).
a Adjusted for age at first full-term pregnancy and region of residence.
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within 3 years prior to cancer diagnosis for which the trend
test was statistically significant. However, there have been
no previous reports of significant inverse association among
women with sufficient serum vitamin D concentrations, a rel-
ative rarity in Finland, despite dietary fortification pro-
grammes since 1994. Previous studies by Tworoger et al. and
us have observed borderline inverse associations among such
groups.5,6
The present results differ slightly when compared to our
earlier study within this cohort.5 In that study, we conjectured
that one of the reasons why no association was apparent
could be because of the low serum 25-OHD within that cohort
subset. This may hold true because the median serum 25-
OHD among cases and controls in the present study is about
5 nmol/L higher than that of our earlier study. It also suggests
that a minimum level of serum vitamin D is necessary to offer
protection against ovarian cancer and in population groups
where serum vitamin D concentrations are low; such protec-
tive effects may not be evident.
A recent large study observed a significant positive rela-
tionship between the number of FOK1 f alleles and ovarian
cancer risk suggesting that the vitamin D pathway indeed
plays a role in ovarian carcinogenesis,31 but perhaps not in
direct conjunction with calcium metabolism. Studies on the
association between vitamin D receptor polymorphism
and the risk of ovarian cancer have yielded conflicting
results31–33, indicating that the modes of action of vitamin D
in the ovarian cancer context remain open.
4.3. Joint effects of vitamin D and calcium in ovarian
cancer
We observed no evidence of a synergistic interaction between
serumvitaminDandcalciumonovariancancer risk.While cal-
ciumwas independentlyassociatedwitha reducedriskofovar-
ian cancer irrespective of vitamin D levels, vitamin D was
independentlyassociatedwithanon-significantly reduced risk
of ovarian cancer. This suggests that the protective effects ob-
served among women with high calcium and high vitamin D
levels were likely to bemediated by the effects of high calcium
levels. The concept of a possible synergistic effect of vitamin D
andcalciumonhealth outcomeshas beenproposedbecauseof
coherent observations in experimental and epidemiological
studies. Calcium mediates vitamin D-induced apoptosis in
breast cells34 suggesting that parts of the apoptotic effects of
vitaminD aremade possible via calciumdependent processes.
It has been shown that calcium deficiency promotes vitamin D
deficiencyandvitaminD requirements increasedwhendietary
calcium reduces.35 The randomised controlled trial conducted
in United States also observed a reduced risk of total cancer
among women on calcium supplementation but a more
marked risk reduction among women on combined cal-
cium + vitamin D supplementation. Likewise, signalling path-
ways for VDR and CaR converge on the same pathway giving
rise to possibilities of interaction.9
4.4. Methodological issues
Our study has the following limitations. We did not have
information on oral contraceptive use, family history of ovar-
ian cancer and BMI which may influence our results; hence
there may be residual confounding. It is however very likely
that if the women were using oral contraceptives, they must
have stopped for some months before the samples were
was taken since they were pregnant women and the samples
were taken between the 12th and 14th week of pregnancy.
Also, our study subjects were limited to fertile women in their
reproductive ages, hence we cannot generalise our results to
infertile/and/or post-menopausal women.
The use of single-point biomarker measurement in deter-
mining risks may be questioned but studies have shown that
there is a high individual correlation in 25-OHD concentra-
tions over a 5 year period36 and both 25-OHD and calcium ex-
hibit low long-term intra-individual variations.36,37 Likewise,
we do not think pregnancy has affected the relationship be-
tween calcium, vitamin D and ovarian cancer because it has
been shown that the serum calcium and 25-OHD concentra-
tions are not appreciably different from the pre-pregnancy
levels,38 a result corroborated in our study whereby there
was no correlation between gestational days and the two
biomarkers.
In conclusion, calcium and vitamin D act independently to
reduce ovarian cancer risk. While we observed a significant
inverse association between calcium and ovarian cancer,
the association between vitamin D and ovarian cancer was
of borderline significance. The relationship between calcium
and ovarian cancer is novel and intriguing, but needs to be
validated in other studies as this could present new opportu-
nities in ovarian cancer prevention.
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Abstract: 
We studied the association of over time vitamin D status with ovarian cancer 
risk in 90 matched case/control pairs who donated serial samples either 
during winter or summer seasons. Mean lag time between sample 
withdrawals was 2.6 years. Women whose serum 25-OHD concentrations 
were continuously above the summer season-specific median had a 
decreased risk of ovarian cancer compared to women with below median 
concentrations, OR 0.21 (95% CI 0.05-0.99). Women who consistently 
maintain high serum 25-OHD levels over many years may have lower risks of 
ovarian cancer.  
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Vitamin D status is inversely associated with ovarian cancer risk [1,2,3]. Same 
season levels of serum 25-OHD levels are reproducible over long time 
periods [4, 5, 6]. Thus, the use of one-point serum 25-OHD measurement is 
adequate in epidemiology but, the ethiopathogenetic impact of pre-diagnostic 
changes in vitamin D status should be elaborated.  
We measured serum 25-OHD concentrations in samples donated 
over consecutive pregnancies before ovarian cancer diagnosis in the 
population-based Finnish Maternity Cohort (FMC), established by the National 
Institute for Health and Welfare (THL), Finland in 1983 [7]. Following an 
informed consent, first trimester serum samples are withdrawn at the 
municipal maternity care units to screen for intrauterine infections. The 
remaining sample (1-3 mL of serum) is stored at -25 ºC at the THL, Oulu. 
Since 1983, 750,000 women (> 98% of pregnant Finnish women) have 
donated samples to the cohort.  
 Incident ovarian cancer cases were identified by the population- 
based Finnish Cancer Registry (FCR). All cancer cases diagnosed in Finland 
since 1953 have been reported to the FCR, with practically no losses to 
follow-up [8]. Eligible cases were 172 women who had donated a minimum of 
two serum samples to the FMC, the second sample donated at least one year 
before cancer diagnosis and the first sample at least one year earlier. 
Eligible controls (1:1) were women who were alive and free of 
cancer at the time of diagnosis of the index case, and had donated at least 
two serum samples during consecutive pregnancies to the FMC. The controls 
were matched for (i) age at sample withdrawal ± 1 year, (ii) parity, and (iii) 
date of index blood sampling ± 2 weeks for both sets of samples.  
Eventually, only cases and controls who donated both serum 
samples within the same season were selected to avoid confounding due to 
differences in the sampling seasons. There were 53 case/control pairs (mean 
ages at the first and second serum samplings; 27.7/27.5 and 30.1/30.1 years) 
whose 1st and 2nd samples were donated during winter and 37 case/control 
pairs (mean ages at the first and second serum samplings; 27.7/27.8 and 
30.5/30.3 years) whose 1st and 2nd samples were donated during summer. 
The average time difference between the 1st and the 2nd samplings was 2.6 
years 
4 
 
The study was approved by the ethical committee of the National 
Institute for Health and Welfare, Finland.  
  Quantification of 25-OHD was performed at the Department of 
Medical Biosciences, University of Umeå, Sweden using a 25-OHD 
radioimmunoassay (IDS Ltd, Boldon, UK). The manufacturer stated a 
specificity (% cross-reactivity) of 100% for 25-OHD3, 75% for 25-OHD2, 
100% for 24, 25-OH2D3, and less than 0.01% and 0.3% for cholecalciferol 
(D3), and ergocalciferol (D2), respectively. The within, between, and total 
coefficients of variation of the assay were 4.3%, 17.1%, and 17.7% at level 
32.9 nmol/L, respectively. 
 We divided the women into four groups based on the median 25-
OHD concentrations for both 1st and 2nd samples. (i) Women with 25-OHD 
concentrations below the season-specific median values during both 1st and 
2nd sampling periods (reference category), (ii) Women with 25-OHD 
concentration below the median value during the 1st sampling period but 
above the median value during the 2nd sampling period, (iii) 25-OHD 
concentration above the median value during the 1st sampling period but 
below the median value during the 2nd sampling period, (iv) 25-OHD 
concentrations above the median values during the 1st and 2nd sampling 
periods.  
Correlation between the 25-OHD concentrations was assessed with 
the Pearson correlation coefficient. Relative risk of ovarian cancer (odds ratio, 
OR with 95% confidence interval, CI) was calculated using the conditional 
logistic regression and adjusted for age at first full term pregnancy and region 
of residence (south, west, central, east and northern Finland).  All statistical 
analyses were performed using SPSS 18 for windows (SPSS, Inc., Chicago, 
IL), assuming two-sided p < 0.05.  
Among women who donated samples during winter, the mean 25-OHD 
concentrations for 1st and 2nd samples were 39.3 and 37.4 nmol/L, 
respectively while during summer the mean 25-OHD concentrations for 1st 
and 2nd samples were 51.5 and 52.0 nmol/L respectively. Correlation between 
the 1st and 2nd sample serum 25-OHD concentrations was highly significant 
for both summer combinations (rs = 0.60, p-value ≤ 0.001) and winter 
5 
 
combinations (rs = 0.39, p-value = 0.004) for the controls but not cases (r = 
0.25 and 0.16 respectively (figure 1) 
Among women who donated their samples during summer season, 
having both serum 25-OHD concentrations above the median values was 
associated with a reduced risk of ovarian cancer, OR 0.21 (95% CI 0.05-0.99) 
(table 1). A protective trend for vitamin D levels increasing over time was 
noted albeit with borderline statistical significance (p-trend = 0.06, table 1). 
 Our study suggests that high serum 25-OHD levels during 
summer season over a longer period of time, average of 2.7 years, was 
associated with an inverse risk of ovarian cancer. The correlation (r = 0.47) 
between samples donated during summer is very similar to that observed in 
the Norwegian study (between 0.42 and 0.52) [4] indicating good tracking of 
vitamin D status by serum 25-OHD levels. In this context, the lack of 
correlation between 1st and 2nd sample 25-0HD concentrations among the 
cases is noteworthy and suggest that ethiopathogenetically relevant changes 
may occur in women due to develop ovarian cancer. Experimentally, it has 
been shown that high levels of vitamin D are needed to protect against 
ovarian carcinogenesis [9]. At some stage, women developing ovarian cancer 
deviate from consistent long-term serum 25-OHD levels.  
The generally low serum 25-OHD levels observed during winter 
are noteworthy. Solar ultraviolet radiation is a function of the solar zenith 
angles which are very large and oblique in winter resulting in lower ultraviolet 
rays compared to summer [10]. In essence, the UVB irradiation threshold of 
18 mJ/cm2 required to induce vitamin D production is not reached during 
winter in Finland and most people have vitamin D insufficiency at least half a 
year [10]. The ethiopathogenetic impact of failing to maintain appropriate 
vitamin D status over time and subsequent risk of ovarian cancer warrant 
further investigation.  
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